Agenus (AGEN) 10-Q 9 Aug 18 2018 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2018	Aug. 03, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2018
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2,018
Entity Registrant Name	AGENUS INC
Entity Central Index Key	1,098,972
Trading Symbol	AGEN
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		113,282,116

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
ASSETS
Cash and cash equivalents	$ 43,163,886	$ 60,186,617
Inventories	55,491	79,491
Accounts receivable	10,919,713	1,134,493
Prepaid expenses	12,916,189	11,070,960
Other current assets	649,552	1,081,993
Total current assets	67,704,831	73,553,554
Property, plant and equipment, net of accumulated amortization and depreciation of $36,032,383 and $34,029,085 at June 30, 2018 and December 31, 2017, respectively	26,922,101	26,178,622
Goodwill	22,814,031	23,048,804
Acquired intangible assets, net of accumulated amortization of $6,476,682 and $5,461,834 at June 30, 2018 and December 31, 2017, respectively	13,280,795	14,406,650
Other long-term assets	1,214,394	1,214,394
Total assets	131,936,152	138,402,024
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current portion, long-term debt	146,061	20,639,735
Current portion, liability related to sale of future royalties	18,580,160
Current portion, deferred revenue	946,775	4,484,882
Accounts payable	10,233,600	8,086,992
Accrued liabilities	20,992,107	21,569,449
Other current liabilities	418,547	1,657,063
Total current liabilities	51,317,250	56,438,121
Long-term debt, net of current portion	12,907,352	142,385,024
Liability related to sale of future royalties, net of current portion	172,997,880
Deferred revenue, net of current portion	1,627,786	7,748,284
Contingent purchase price considerations	3,097,000	4,373,000
Other long-term liabilities	3,075,757	3,273,387
Commitments and contingencies
STOCKHOLDERS’ DEFICIT
Common stock, par value $0.01 per share; 240,000,000 shares authorized; 111,198,400 and 101,706,117 shares issued at June 30, 2018 and December 31, 2017, respectively	1,111,984	1,017,061
Additional paid-in capital	984,189,044	951,811,958
Accumulated other comprehensive loss	(1,577,617)	(2,169,354)
Accumulated deficit	(1,096,430,845)	(1,026,475,773)
Total stockholders’ deficit attributable to Agenus Inc.	(112,707,118)	(75,815,792)
Non-controlling interest	(379,755)
Total stockholders’ deficit	(113,086,873)	(75,815,792)
Total liabilities and stockholders’ deficit	131,936,152	138,402,024
Series A-1 convertible preferred stock [Member]
STOCKHOLDERS’ DEFICIT
Preferred stock, par value $0.01 per share; 5,000,000 shares authorized: Series A-1 convertible preferred stock; 31,620 shares designated, issued, and outstanding at June 30, 2018 and December 31, 2017; liquidation value of $32,676,808 at June 30, 2018	$ 316	$ 316

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Property plant and equipment, accumulated amortization and depreciation	$ 36,032,383	$ 34,029,085
Acquired intangible assets, accumulated amortization	$ 6,476,682	$ 5,461,834
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	240,000,000	240,000,000
Common stock, shares issued	111,198,400	101,706,117
Series A-1 convertible preferred stock [Member]
Series A-1 convertible preferred stock, shares designated	31,620	31,620
Series A-1 convertible preferred stock, shares issued	31,620	31,620
Series A-1 convertible preferred stock, shares outstanding	31,620	31,620
Series A-1 convertible preferred stock, liquidation value	$ 32,728,478

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Revenue:
Total revenues	$ 15,894,625	$ 4,207,573	$ 17,530,666	$ 31,163,416
Operating expenses:
Research and development	(29,273,528)	(25,824,431)	(58,714,813)	(58,464,422)
General and administrative	(9,485,114)	(8,136,252)	(18,412,673)	(15,905,760)
Contingent purchase price consideration fair value adjustment	6,292,000	865,000	1,276,000	1,061,000
Operating loss	(16,572,017)	(28,888,110)	(58,320,820)	(42,145,766)
Other expense:
Loss on early extinguishment of debt			(10,766,625)
Non-operating income (expense)	(2,407,838)	1,649,811	(1,372,663)	2,389,946
Interest expense, net	(6,223,925)	(4,474,743)	(9,004,815)	(9,060,400)
Net loss	(25,203,780)	(31,713,042)	(79,464,923)	(48,816,220)
Dividends on Series A-1 convertible preferred stock	(51,670)	(51,344)	(103,259)	(102,608)
Less: net loss attributable to non-controlling interest	(532,725)		(653,355)
Net loss attributable to Agenus Inc. common stockholders	$ (24,722,725)	$ (31,764,386)	$ (78,914,827)	$ (48,918,828)
Per common share data:
Basic and diluted net loss attributable to Agenus Inc. common stockholders	$ (0.24)	$ (0.32)	$ (0.76)	$ (0.51)
Weighted average number of Agenus Inc. common shares outstanding:
Basic and diluted	105,112,976	99,201,975	103,851,662	96,370,777
Other comprehensive loss:
Foreign currency translation (loss) gain	$ 1,128,808	$ (628,456)	$ 591,737	$ (760,295)
Other comprehensive (loss) income	1,128,808	(628,456)	591,737	(760,295)
Comprehensive loss	(23,593,917)	(32,392,842)	(78,323,090)	(49,679,123)
Research and Development [Member]
Revenue:
Total revenues	10,472,934	$ 4,207,573	12,108,975	$ 31,163,416
Non-Cash Royalty Revenue Related to the Sale of Future Royalties [Member]
Revenue:
Total revenues	$ 5,421,691		$ 5,421,691

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Cash flows from operating activities:
Net loss	$ (79,464,923)	$ (48,816,220)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	3,109,259	3,057,142
Share-based compensation	3,790,084	5,129,035
Non-cash royalty revenue	(5,421,691)
Non-cash interest expense	8,724,977	8,783,464
Loss on disposal of assets	77,991	9,209
Gain on issuance of stock for settlement of milestone obligation		(14,063)
Change in fair value of contingent obligations	(1,276,000)	(1,061,000)
Loss on extinguishment of debt	10,766,625
Changes in operating assets and liabilities:
Accounts receivable	(9,785,220)	7,408,118
Inventories	24,000
Prepaid expenses	(1,852,015)	(6,330,969)
Accounts payable	1,669,457	(1,225,694)
Deferred revenue	(802,111)	(1,117,884)
Accrued liabilities and other current liabilities	(872,958)	(6,032,357)
Other operating assets and liabilities	533,071	(2,000,691)
Net cash used in operating activities	(70,779,454)	(42,211,910)
Cash flows from investing activities:
Proceeds from sale of plant and equipment	5,218	120,000
Purchases of plant and equipment	(2,175,605)	(1,405,932)
Purchases of held-to-maturity securities		(14,936,047)
Proceeds from securities held-to-maturity		5,000,000
Net cash used in investing activities	(2,170,387)	(11,221,979)
Cash flows from financing activities:
Net proceeds from sale of equity	27,894,865	63,677,302
Proceeds from employee stock purchases and option exercises	1,060,660	342,476
Purchase of treasury shares to satisfy tax withholdings		(527,223)
Proceeds from sale of future royalties	189,878,400
Transaction costs from sale of future royalties	(494,394)
Repayments of debt	(161,847,223)
Payment of capital lease obligation	(129,372)	(133,300)
Net cash provided by financing activities	56,362,936	63,359,255
Effect of exchange rate changes on cash	(435,826)	456,347
Net (decrease) increase in cash and cash equivalents	(17,022,731)	10,381,713
Cash and cash equivalents, beginning of period	60,186,617	71,448,016
Cash and cash equivalents, end of period	43,163,886	81,829,729
Supplemental cash flow information:
Cash paid for interest	555,397	555,397
Supplemental disclosures - non-cash activities:
Purchases of plant and equipment in accounts payable and accrued liabilities	$ 804,056	355,814
Milestone obligation [Member]
Supplemental disclosures - non-cash activities:
Issuance of common stock, $0.01 par value, issued in connection with the settlement of milestone obligation		$ 1,485,937

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)	Jun. 30, 2018$ / shares
Supplemental disclosures - non-cash activities:
Common stock, par value	$ 0.01
Milestone obligation [Member]
Supplemental disclosures - non-cash activities:
Common stock, par value	$ 0.01

Business, Liquidity and Basis o

Business, Liquidity and Basis of Presentation	6 Months Ended
	Jun. 30, 2018
Description Of Business [Abstract]
Business, Liquidity And Basis of Presentation	Note A - Business, Liquidity and Basis of Presentation Agenus Inc. (including its subsidiaries, collectively referred to as “Agenus,” the “Company,” “we,” “us,” and “our”) is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. Our business is designed to drive success in I-O through speed, innovation, and effective combination therapies. We have assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants, cancer vaccine platforms, and cell therapy (through our subsidiary, AgenTus Therapeutics, Inc. (“AgenTus Therapeutics”)). We leverage our immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance our innovation. We are developing a comprehensive I-O portfolio driven by the following platforms and programs, which we intend to utilize individually and in combination: • our antibody discovery platforms, including our Retrocyte Display™, SECANT ® • our antibody candidate programs, including our CPM programs; • our vaccine programs, including Prophage™, AutoSynVax™ and PhosPhoSynVax • our saponin-based vaccine adjuvants, principally our QS-21 Stimulon ® • our cell therapy subsidiary, AgenTus Therapeutics, which is designed to drive the discovery of future adoptive cell therapy, or “living drugs” (CAR-T and TCR) programs. Our business activities include product research and development, intellectual property prosecution, manufacturing, regulatory and clinical affairs, corporate finance and development activities, and support of our collaborations. Our product candidates require clinical trials and approvals from regulatory agencies, as well as acceptance in the marketplace. Part of our strategy is to develop and commercialize some of our product candidates by continuing our existing arrangements with academic and corporate collaborators and licensees and by entering into new collaborations. Our cash and cash equivalents at June 30, 2018 were $43.2 million, a decrease of $17.0 million from December 31, 2017. The following table outlines our quarter end cash and cash equivalents balances and the changes therein (in millions). Quarter Ended March 31, 2018 June 30, 2018 Cash and cash equivalents $ 52.3 $ 43.2 Decrease in cash and cash equivalents $ (7.8 ) $ (9.2 ) Cash used in operating activities $ (40.2 ) $ (30.5 ) Reported net loss $ (54.3 ) $ (25.2 ) Our future liquidity needs will be determined primarily by the success of our operations with respect to the progression of our product candidates and key development and regulatory events in the future. Potential sources of additional funding include: (1) pursuing collaboration, out-licensing and/or partnering opportunities for our portfolio programs and product candidates with one or more third parties, (2) renegotiating third party agreements, (3) selling assets, (4) securing additional debt financing and/or (5) selling equity securities. We believe the execution of one or more of these transactions will enable us to fund our planned operations for at least one year from when these financial statements were issued. Our ability to address our liquidity needs will largely be determined by the success of our product candidates and key development and regulatory events and our decisions in the future as well as the execution of one or more of the aforementioned contemplated transactions. The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete annual consolidated financial statements. In the opinion of our management, the condensed consolidated financial statements include all normal and recurring adjustments considered necessary for a fair presentation of our financial position and operating results. All significant intercompany transactions and accounts have been eliminated in consolidation. Operating results for the six months ended June 30, 2018, are not necessarily indicative of the results that may be expected for the year ending December 31, 2018. For further information, refer to our consolidated financial statements and footnotes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2017 filed with the Securities and Exchange Commission (the “SEC”) on March 16, 2018. The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances. Actual results could differ materially from those estimates. For our foreign subsidiaries the local currency is the functional currency. Assets and liabilities of our foreign subsidiaries are translated into U.S. dollars using rates in effect at the balance sheet date while revenues and expenses are translated into U.S. dollars using average exchange rates during the period. The cumulative translation adjustment resulting from changes in exchange rates are included in the consolidated balance sheets as a component of accumulated other comprehensive loss in total stockholders’ deficit.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note B - Summary of Significant Accounting Policies Except as detailed below, there have been no material changes to our significant accounting policies during the six months ended June 30, 2018, as compared to the significant accounting policies disclosed in Note 2 of the Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017. Revenue In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes existing revenue recognition guidance. We adopted ASU 2014-09 and its related amendments (collectively known as “ASC 606”) on January 1, 2018 using the modified retrospective method- i.e., by recognizing the cumulative effect of initially applying ASC 606 as an adjustment to the opening balance of equity at January 1, 2018. The reported results for 2018 reflect the application of ASC 606 guidance while the reported results for 2017 were prepared under the guidance of ASC 605, Revenue Recognition (“ASC 605”). The adoption of ASC 606 represents a change in accounting principle that will more closely align revenue recognition with the delivery of our goods and services and will provide financial statement readers with enhanced disclosures. The details of the significant changes and quantitative impact of the changes are disclosed in Note J. In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which we expect to be entitled to receive in exchange for these goods and services. To achieve this core principle, we apply the following five steps: 1) Identify the contract with the customer A contract with a customer exists when (i) the Company enters into an enforceable contract with a customer that defines each party’s rights regarding the goods or services to be transferred and identifies the related payment terms, (ii) the contract has commercial substance, and (iii) the Company determines that collection of substantially all consideration for goods and services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration. The Company applies judgment in determining the customer’s intent and ability to pay, which is based on a variety of factors including the customer’s historical payment experience, or in the case of a new customer, published credit and financial information pertaining to the customer. 2) Identify the performance obligations in the contract Performance obligations promised in a contract are identified based on the goods and services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the good or service either on its own or together with other available resources, and are distinct in the context of the contract, whereby the transfer of the good or service is separately identifiable from other promises in the contract. To the extent a contract includes multiple promised goods and services, the Company must apply judgment to determine whether promised goods and services are capable of being distinct and are distinct in the context of the contract. If these criteria are not met, the promised goods and services are accounted for as a combined performance obligation. 3) Determine the transaction price The transaction price is determined based on the consideration to which the Company will be entitled in exchange for transferring goods and services to the customer. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing either the expected value method or the most likely amount method depending on the nature of the variable consideration. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Any estimates, including the effect of the constraint on variable consideration, are evaluated at each reporting period for any changes. Determining the transaction price requires significant judgment, which is discussed in further detail for each of the Company’s contracts with customers in Note J. 4) Allocate the transaction price to performance obligations in the contract If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation on a relative stand-alone selling price basis unless the transaction price is variable and meets the criteria to be allocated entirely to a performance obligation or to a distinct service that forms part of a single performance obligation. The consideration to be received is allocated among the separate performance obligations based on relative stand-alone selling prices. Determining the amount of the transaction price to allocate to each separate performance obligation requires significant judgement, which is discussed in further detail for each of the Company’s contracts with customers in Note J. 5) Recognize revenue when or as the Company satisfies a performance obligation The Company satisfies performance obligations either over time or at a point in time. Revenue is recognized over time if either 1) the customer simultaneously receives and consumes the benefits provided by the entity’s performance, 2) the entity’s performance creates or enhances an asset that the customer controls as the asset is created or enhanced, or 3) the entity’s performance does not create an asset with an alternative use to the entity and the entity has an enforceable right to payment for performance completed to date. If the entity does not satisfy a performance obligation over time, the related performance obligation is satisfied at a point in time by transferring the control of a promised good or service to a customer. Examples of control are using the asset to produce goods or services, enhance the value of other assets, settle liabilities, and holding or selling the asset. ASC 606 requires the Company to select a single revenue recognition method for the performance obligation that faithfully depicts the Company’s performance in transferring control of the goods and services. The guidance allows entities to choose between two methods to measure progress toward complete satisfaction of a performance obligation: 1. Output methods - recognize revenue on the basis of direct measurements of the value to the customer of the goods or services transferred to date relative to the remaining goods or services promised under the contract (e.g. surveys of performance completed to date, appraisals of results achieved, milestones reached, time elapsed, and units of produced or units delivered); and 2. Input methods - recognize revenue on the basis of the entity’s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation. Licenses of intellectual property: If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Milestone payments: At the inception of each arrangement that includes development, regulatory or commercial milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. Whichever method is used, it should be consistently applied throughout the life of the contract; however, it is not necessary for the Company to use the same approach for all contracts. The Company uses the most likely amount method for development and regulatory milestone payments. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. Royalties: For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Up-front Fees: Depending on the nature of the agreement, up-front payments and fees may be recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company’s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less. Impact of Adopting ASC 606 on Financial Statements We adopted ASC 606 using the modified retrospective method. The cumulative effect of applying the new guidance to all contracts with customers that were not completed as of January 1, 2018 was recorded as an adjustment to accumulated deficit as of the adoption date. We elected to apply a practical expedient to reflect the aggregate effect of all modifications that occurred before January 1, 2018 when identifying the satisfied and unsatisfied performance obligations, determining the transaction price, and allocating the transaction price to the satisfied and unsatisfied performance obligations. The estimated effect of applying this practical expedient results in a slower recognition of the transaction price, as more consideration is allocated to performance obligations originally identified as a material right at contract inception. As a result of applying the modified retrospective method to adopt the new revenue guidance, the following adjustments were made to the consolidated balance sheet as of January 1, 2018 (in thousands): As Reported December 31, 2017 ASC 606 Adjustment Adjusted January 1, 2018 Consolidated Balance Sheet Data: Current portion, deferred revenue $ 4,485 $ (2,986 ) $ 1,499 Deferred revenue, net of current portion 7,748 (5,870 ) 1,878 Accumulated deficit $ (1,026,476 ) $ 8,856 $ (1,017,620 ) Impact of ASC 606 on Financial Statements In accordance with Topic 606, the disclosure of the impact of adoption to our condensed consolidated statements of income and balance sheets was as follows (in thousands): Six months ended June 30, 2018 As Reported Under ASC 606 Adjustments Notes Balances without Adoption of ASC 606 Consolidated Balance Sheet Data: Accounts receivable $ 10,920 $ (4,000 ) (1 ) $ 6,920 Current portion, deferred revenue 947 942 (2 ) 1,889 Deferred revenue, net of current portion 1,628 5,176 (2 ) 6,804 Accumulated deficit (1,096,431 ) (10,118 ) (3 ) (1,106,549 ) Consolidated Statement of Operations Data: Research and development revenue $ 12,109 $ (1,261 ) (4 ) $ 10,848 Three months ended June 30, 2018 Consolidated Statement of Operations Data: Research and development revenue $ 10,473 $ (1,842 ) (4 ) $ 8,631 (1) Adjustment to accounts receivable to reflect a milestone recognized under ASC 606 and included in accounts receivable on June 30, 2018. (2) Adjustment to deferred revenue to reflect recognition of revenue under ASC 605 primarily attributable to the change in the timing of revenue recognition for amounts received under the Incyte Collaboration Agreement, see Note J. (3) Adjustment to accumulated deficit to reflect the reversal of the cumulative transition adjustment and the difference in revenue from ASC 606 to ASC 605, see Note J. (4) Adjustment to reflect the difference in revenue recognition from ASC 606 to ASC 605 primarily attributable to the recognition of a milestone under ASC 606 that was partially offset by the change in recognition of an upfront fee related to the GSK License and Amended Supply Agreements, see Note J.

Net Loss Per Share

Net Loss Per Share	6 Months Ended
	Jun. 30, 2018
Earnings Per Share [Abstract]
Earnings Per Share	Note C - Net Loss Per Share Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding (including common shares issuable under our Directors’ Deferred Compensation Plan, or “DDCP”). Diluted income per common share is calculated by dividing net income attributable to common stockholders by the weighted average number of common shares outstanding (including common shares issuable under our DDCP) plus the dilutive effect of outstanding instruments such as warrants, stock options, non-vested shares, convertible preferred stock, and convertible notes. Because we reported a net loss attributable to common stockholders for all periods presented, diluted loss per common share is the same as basic loss per common share, as the effect of utilizing the fully diluted share count would have reduced the net loss per common share. Therefore, the following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding as of June 30, 2018 and 2017, as they would be anti-dilutive: Three and Six Months Ended June 30, 2018 2017 Warrants 2,900,000 4,351,450 Stock options 17,060,747 15,287,781 Non-vested shares 2,011,079 2,022,324 Convertible preferred stock 333,333 333,333

Investments

Investments	6 Months Ended
	Jun. 30, 2018
Cash And Cash Equivalents [Abstract]
Investments	Note D - Investments Cash equivalents consisted of the following as of June 30, 2018 and December 31, 2017 (in thousands): June 30, 2018 December 31, 2017 Cost Estimated Fair Value Cost Estimated Fair Value Institutional money market funds $ 39,372 $ 39,372 $ 57,036 $ 57,036 As a result of the short-term nature of our investments, there were minimal unrealized holding gains or losses for the three and six months ended June 30, 2018 and 2017.

Goodwill and Acquired Intangibl

Goodwill and Acquired Intangible Assets	6 Months Ended
	Jun. 30, 2018
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Acquired Intangible Assets	Note E - Goodwill and Acquired Intangible Assets The following table sets forth the changes in the carrying amount of goodwill for the six months ended June 30, 2018 (in thousands): Balance, December 31, 2017 $ 23,049 Foreign currency translation adjustment (235 ) Balance, June 30, 2018 $ 22,814 Acquired intangible assets consisted of the following as of June 30, 2018 and December 31, 2017 (in thousands): As of June 30, 2018 Amortization period (years) Gross carrying amount Accumulated amortization Net carrying amount Intellectual property 7-15 years $ 16,478 $ (5,205 ) $ 11,273 Trademarks 4.5 years 814 (791 ) 23 Other 2-6 years 568 (481 ) 87 In-process research and development Indefinite 1,898 — 1,898 Total $ 19,758 $ (6,477 ) $ 13,281 As of December 31, 2017 Amortization period (years) Gross carrying amount Accumulated amortization Net carrying amount Intellectual property 7-15 years $ 16,545 $ (4,290 ) $ 12,255 Trademarks 4.5 years 826 (711 ) 115 Other 2-6 years 570 (461 ) 109 In-process research and development Indefinite 1,928 — 1,928 Total $ 19,869 $ (5,462 ) $ 14,407 The weighted average amortization period of our finite-lived intangible assets is 9 years. Amortization expense related to acquired intangibles is estimated at $1.0 million for the remainder of 2018 and $1.9 million for each of the years ending December 31, 2019, 2020, 2021 and 2022.

Debt

Debt	6 Months Ended
	Jun. 30, 2018
Debt Disclosure [Abstract]
Debt	Note F - Debt Debt obligations consisted of the following as of June 30, 2018 and December 31, 2017 (in thousands): Debt instrument Principal at June 30, 2018 Non-cash Interest Unamortized Debt Issuance Costs Unamortized Debt Discount Balance at June 30, 2018 Current Portion: Debentures $ 146 $ — $ — $ — $ 146 Long-term Portion: 2015 Subordinated Notes 14,000 — — (1,093 ) 12,907 Total $ 14,146 $ — $ — $ (1,093 ) $ 13,053 Debt instrument Principal at December 31, 2017 Non-cash Interest Unamortized Debt Issuance Costs Unamortized Debt Discount Balance at December 31, 2017 Current Portion: Debentures $ 146 $ — $ — $ — $ 146 Note Purchase Agreement 15,000 5,494 — — 20,494 Total current 15,146 5,494 — — 20,640 Long-term Portion: 2015 Subordinated Notes 14,000 — — (1,375 ) 12,625 Note Purchase Agreement 100,000 31,323 (1,362 ) (201 ) 129,760 Total long-term 114,000 31,323 (1,362 ) (1,576 ) 142,385 Total $ 129,146 $ 36,817 $ (1,362 ) $ (1,576 ) $ 163,025 We have capital lease agreements that expire in 2020 for equipment with a carrying value of approximately $1.0 million, which is included in property, plant and equipment, net on our condensed consolidated balance sheet. Under the terms of the capital lease agreements, we will remit payments to the lessors of $190,000 for the remainder of 2018, $375,000 for the year ending December 31, 2019 and $165,000 for the year ending December 31, 2020. As of June 30, 2018, our remaining obligation under the capital lease agreements is approximately $0.7 million, of which $360,000 and $330,000 are classified as other current and other long-term liabilities, respectively, on our condensed consolidated balance sheet. In January 2018, we, through our wholly-owned subsidiary, Antigenics LLC (“Antigenics”), entered into a Royalty Purchase Agreement (the “Royalty Purchase Agreement”) with Healthcare Royalty Partners III, L.P., and certain of its affiliates (collectively “HCR”), whereby we received gross proceeds of $190.0 million (refer to Note G). Concurrently with the closing of the Royalty Purchase Agreement, we used $161.9 million of these proceeds to redeem Antigenics’ $115.0 million principal amount of notes issued pursuant to the Note Purchase Agreement dated September 4, 2015 with Oberland Capital SA Zermatt LLC and the purchasers named therein (the “Note Purchase Agreement”), as well as the associated accrued and unpaid interest, and the Note Purchase Agreement and the notes issued thereunder were redeemed in full and terminated. In connection with this redemption, we recorded a $10.8 million loss on early extinguishment of debt which primarily reflects the payment of premiums to fully redeem the notes and the write-off of unamortized debt issuance costs and discounts.

Liability Related to the Sale o

Liability Related to the Sale of Future Royalties	6 Months Ended
	Jun. 30, 2018
Liability Related To Sale Of Future Royalties [Abstract]
Liability Related to the Sale of Future Royalties	Note G – Liability Related to the Sale of Future Royalties On January 6, 2018, we, through Antigenics, entered into the Royalty Purchase Agreement with HCR, which closed on January 19, 2018. Pursuant to the terms of the Royalty Purchase Agreement, we sold to HCR 100% of Antigenics’ worldwide rights to receive royalties from GlaxoSmithKline (“GSK”) on sales of GSK’s vaccines containing our QS-21 Stimulon adjuvant. At closing, we received gross proceeds of $190.0 million from HCR. As part of the transaction, we reimbursed HCR for transaction costs of $100,000 and incurred approximately $500,000 in transaction costs of our own, which are presented net of the liability in the consolidated balance sheet and will be amortized to interest expense over the estimated life of the Royalty Purchase Agreement. Although we sold all of our rights to receive royalties on sales of GSK’s vaccines containing QS-21, as a result of our obligation to HCR, we are required to account for these royalties as revenue when earned, and we recorded the $190.0 million in proceeds from this transaction as a liability (“Liability Related to Sale of Future Royalties”) on our condensed consolidated balance sheet that will be amortized using the interest method over the estimated life of the Royalty Purchase Agreement. The liability is classified between the current and non-current portion of liability related to sale of future royalties in the consolidated balance sheets based on the estimated recognition of the royalty payments to be received by HCR in the next 12 months from the financial statement reporting date. The following table shows the activity within the liability account from the inception of the royalty agreement in January 2018 to June 30, 2018 (in thousands): Period from inception to June 30, 2018 Liability related to sale of future royalties - beginning balance $ — Proceeds from sale of future royalties 190,000 Non-cash royalty revenue (5,422 ) Non-cash interest expense recognized 7,565 Liability related to sale of future royalties - ending balance 192,143 Less: unamortized transaction costs (565 ) Liability related to sale of future royalties, net $ 191,578 During the six months ended June 30, 2018, we recognized $5.4 million of non-cash royalty revenue, and we recorded $7.6 million of related non-cash interest expense. As royalties are remitted to HCR from GSK, the balance of the recorded liability will be effectively repaid over the life of the Royalty Purchase Agreement. To determine the amortization of the recorded liability, we are required to estimate the total amount of future royalty payments to be received by HCR. The sum of these amounts less the $190.0 million proceeds we received will be recorded as interest expense over the life of the Royalty Purchase Agreement. Periodically, we assess the estimated royalty payments to be paid to HCR from GSK, and to the extent the amount or timing of the payments is materially different from our original estimates, we will prospectively adjust the amortization of the liability. During the three months ended June 30, 2018, our estimate of the effective annual interest rate over the life of the agreement increased to 12.0%, which results in a prospective interest rate of 12.2%. There are a number of factors that could materially affect the amount and timing of royalty payments from GSK, all of which are not within our control. Such factors include, but are not limited to, changing standards of care, the introduction of competing products, manufacturing or other delays, biosimilar competition, patent protection, adverse events that result in governmental health authority imposed restrictions on the use of the drug products, significant changes in foreign exchange rates, and other events or circumstances that could result in reduced royalty payments from GSK, all of which would result in a reduction of non-cash royalty revenues and the non-cash interest expense over the life of the Royalty Purchase Agreement. Conversely, if sales of GSK’s vaccines containing QS-21 are more than expected, the non-cash royalty revenues and the non-cash interest expense recorded by us would be greater over the life of the Royalty Purchase Agreement. Pursuant to the Royalty Purchase Agreement, we will also be entitled to receive up to $40.4 million in milestone payments based on sales of GSK’s vaccines as follows: (i) $15.1 million upon reaching $2.0 billion last-twelve-months net sales any time prior to 2024 and (ii) $25.3 million upon reaching $2.75 billion last-twelve-months net sales any time prior to 2026. Additionally, pursuant to the Royalty Purchase Agreement, we would owe approximately $25.9 million to HCR in 2021 (the “Rebate Payment”) if neither of the following sales milestones are achieved: (i) 2019 sales exceed $1.0 billion or (ii) 2020 sales exceed $1.75 billion. As part of the transaction, we provided a guaranty for the potential Rebate Payment and secured the obligation with substantially all of our assets pursuant to a security agreement, subject to certain customary exceptions and excluding all assets necessary for AgenTus Therapeutics.

Accrued Liabilities

Accrued Liabilities	6 Months Ended
	Jun. 30, 2018
Other Liabilities Disclosure [Abstract]
Accrued Liabilities	Note H - Accrued Liabilities Accrued liabilities consisted of the following as of June 30, 2018 and December 31, 2017 (in thousands): June 30, 2018 December 31, 2017 Payroll $ 4,920 $ 7,790 Professional fees 2,988 2,021 Contract manufacturing costs 5,339 5,528 Research services 6,653 4,663 Other 1,092 1,567 Total $ 20,992 $ 21,569

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2018
Fair Value Measurements [Abstract]
Fair Value Measurements	Note I - Fair Value Measurements We measure our contingent purchase price considerations at fair value. The fair values of our contingent purchase price considerations, $3.1 million, are based on significant inputs not observable in the market, which require them to be reported as Level 3 liabilities within the fair value hierarchy. The valuation of these liabilities use assumptions we believe would be made by a market participant and are based on estimates from a Monte Carlo simulation of our market capitalization and share price, and other factors impacting the probability of triggering the milestone payments. Market capitalization and share price were evolved using a geometric Brownian motion, calculated daily for the life of the contingent purchase price considerations. Liabilities measured at fair value are summarized below (in thousands): Description June 30, 2018 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Liabilities: Contingent purchase price considerations $ 3,097 $ — $ — $ 3,097 Total $ 3,097 $ — $ — $ 3,097 Description December 31, 2017 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Liabilities: Contingent purchase price consideration $ 4,373 $ — $ — $ 4,373 Total $ 4,373 $ — $ — $ 4,373 The following table presents our liabilities measured at fair value using significant unobservable inputs (Level 3), as of June 30, 2018 (in thousands): Balance, December 31, 2017 $ 4,373 Change in fair value of contingent purchase price considerations during the period (1,276 ) Balance, June 30, 2018 $ 3,097 The estimated fair values of all of our financial instruments, excluding our outstanding debt as of December 31, 2017, approximate their carrying amounts in our condensed consolidated balance sheets. The fair value of our outstanding debt balance at June 30, 2018 and December 31, 2017 was $14.2 million and $205.9 million, respectively, based on the Level 2 valuation hierarchy of the fair value measurements standard using a present value methodology that was derived by evaluating the nature and terms of each note and considering the prevailing economic and market conditions at the balance sheet date. The principal amount of our outstanding debt balance at June 30, 2018 and December 31, 2017 was $14.1 million and $129.1 million, respectively.

Revenue from Contracts with Cus

Revenue from Contracts with Customers	6 Months Ended
	Jun. 30, 2018
Collaboration [Abstract]
Revenue from Contracts with Customers	Note J - Revenue from Contracts with Customers GSK License and Amended GSK Supply Agreements In July 2006, we entered into a license agreement and a supply agreement with GSK for the use of QS-21 Stimulon (the “GSK License Agreement” and the “GSK Supply Agreement”, respectively). In January 2009, we entered into an Amended and Restated Manufacturing Technology Transfer and Supply Agreement (the “Amended GSK Supply Agreement”) under which GSK has the right to manufacture all of its requirements of commercial grade QS-21 Stimulon. GSK is obligated to supply us (or our affiliates, licensees, or customers) certain quantities of commercial grade QS-21 Stimulon for a stated period of time. Under these agreements, GSK paid an upfront license fee of $3.0 million and agreed to pay aggregate milestones of $5.0 million. In July 2007, the Amended GSK Supply Agreement was further amended, and we were paid an additional fixed fee of $7.3 million. In March 2012 we entered into a First Right to Negotiate and Amendment Agreement amending the GSK License Agreement and the Amended GSK Supply Agreement to clarify and include additional rights for the use of our QS-21 Stimulon (the “GSK First Right to Negotiate Agreement”). In addition, we granted GSK the first right to negotiate for the purchase of the Company or certain of our assets, which such rights expired in March 2017. As consideration for entering into the GSK First Right to Negotiate Agreement, GSK paid us an upfront, non-refundable payment of $9.0 million, $2.5 million of which is creditable toward future royalty payments. As of December 31, 2017, we had received all of the potential $24.3 million in upfront and milestone payments related to the GSK Agreements. We were also generally entitled to receive 2% royalties on net sales of prophylactic vaccines for a period of 10 years after the first commercial sale of a resulting GSK product, but we sold these royalty rights to HCR in January 2018 pursuant to the Royalty Purchase Agreement (See Note G). The GSK License and Amended GSK Supply Agreements may be terminated by either party upon a material breach if the breach is not cured within the time specified in the respective agreement. The termination or expiration of the GSK License Agreement does not relieve either party from any obligation which accrued prior to the termination or expiration. Among other provisions, the license rights granted to GSK survive expiration of the GSK License Agreement. The license rights and payment obligations of GSK under the Amended GSK Supply Agreement survive termination or expiration, except that GSK's license rights and future royalty obligations do not survive if we terminate due to GSK's material breach unless we elect otherwise. We assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, GSK, is a customer. We identified the following performance obligations under the contract: (1) an exclusive license to QS-21 in the specified field and related technology transfer; and (2) and exclusive license to QS-21 in an additional field. We determined that the fixed payments of $19.3 million constituted all of the consideration to be included in the transaction price and to be allocated to the performance obligations based on their relative stand-alone selling prices. The fixed upfront consideration is recognized under ASC 606 based on when control of the combined performance obligation is transferred to the customer, which corresponds with the service period (through December 2014). At contract inception, the milestones of $5.0 million had been excluded from the transaction price, as we could not conclude that it was probable a significant reversal would not occur. Event driven milestones are a form of variable consideration as the payments are variable based on the occurrence of future events. As part of its estimation of the amount, we considered numerous factors, including that receipt of the milestones is outside of our control and contingent upon success in future clinical trials and the licensee’s efforts. Recognition of event driven milestones should be recognized when the variable consideration is able to be estimated. As of December 31, 2017, all milestones had been received, and therefore recognized. Any consideration related to royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to GSK and therefore have also been excluded from the transaction price. We will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. For both the three and six months ended June 30, 2018, we recognized $5.4 million in non-cash royalty revenue from GSK. For both the three and six months ended June 30, 2017 we did not recognize any revenue from GSK. The cumulative impact of changing the timing of revenue recognition for the GSK License and Amended GSK Supply Agreements as of January 1, 2018 was a decrease to stockholders' deficit of approximately $2.5 million and a corresponding decrease in deferred revenue of $2.5 million for the portion of the upfront fee creditable toward future royalties, as described above. This amount was included in the transition adjustment, as under ASC 606 it would have been recognized as revenue in March 2012, at the time of the amendment. Merck Collaboration and License Agreement During the quarter ended June 30, 2014, we entered into a collaboration and license agreement with Merck Sharpe & Dohme (“Merck”) to discover and optimize fully-human antibodies against two undisclosed cancer targets using the Retrocyte Display ® For both the three and six months ended June 30, 2018 we recognized $4.0 million in research and development revenue related to the achievement of a milestone. For both the three and six months ended June 30, 2017, we did not recognize any revenue from this agreement. The adoption of ASC 606 did not have an impact on the Merck collaboration and license agreement. Incyte Collaboration Agreement On January 9, 2015 and effective February 19, 2015, we entered into a global license, development and commercialization agreement (the “Collaboration Agreement”) with Incyte Corporation (“Incyte”) pursuant to which the parties plan to develop and commercialize novel immuno-therapeutics using our antibody discovery platforms. The Collaboration Agreement was initially focused on four checkpoint modulator programs directed at GITR, OX40, LAG-3 and TIM-3. In addition to the four identified antibody programs, the parties have an option to jointly nominate and pursue the development and commercialization of antibodies against additional targets during a five-year discovery period which, upon mutual agreement of the parties for no additional consideration, can be extended for an additional three years. In November 2015, we and Incyte jointly nominated and agreed to pursue the development and commercialization of three additional CPM targets. In February 2017, we amended the Collaboration Agreement by entering into a First Amendment to License, Development and Commercialization Agreement (the “Amendment”). See “Amendment” section below. On January 9, 2015, we also entered into the Stock Purchase Agreement with Incyte Corporation whereby, for an aggregate purchase price of $35.0 million, Incyte purchased approximately 7.76 million shares of our common stock. Agreement Structure Under the terms of the Collaboration Agreement, we received non-creditable, nonrefundable upfront payments totaling $25.0 million. In addition, until the Amendment, the parties shared all costs and profits for the GITR, OX40 and two of the additional antibody programs on a 50:50 basis (profit-share products), and we were eligible to receive up to $20.0 million in future contingent development milestones under these programs. Incyte is obligated to reimburse us for all development costs that we incur in connection with the TIM-3, LAG-3 and one of the additional antibody programs (royalty-bearing products) and we are eligible to receive (i) up to $155.0 million in future contingent development, regulatory, and commercialization milestone payments and (ii) tiered royalties on global net sales at rates generally ranging from 6% to 12%. For each royalty-bearing product, we will also have the right to elect to co-fund 30% of development costs incurred following initiation of pivotal clinical trials in return for an increase in royalty rates. Additionally, we had the option to retain co-promotion participation rights in the United States on any profit-share product. Through the direction of a joint steering committee, until the Amendment, the parties anticipated that, for each program, we would serve as the lead for pre-clinical development activities through investigational new drug (“IND”) application filing, and Incyte would serve as the lead for clinical development activities. The parties initiated the first clinical trials of antibodies arising from these programs in 2016. For each additional program beyond GITR, OX40, TIM-3 and LAG-3 that the parties elect to bring into the collaboration, we will have the option to designate it as a profit-share product or a royalty-bearing product. The Collaboration Agreement will continue as long as (i) any product is being developed or commercialized or (ii) the discovery period remains in effect. Incyte may terminate the Collaboration Agreement or any individual program for convenience upon 12 months’ notice. The Collaboration Agreement may also be terminated by either party upon the occurrence of an uncured material breach of the other party or by us if Incyte challenges patent rights controlled by us. In addition, either party may terminate the Collaboration Agreement as to any program if the other party is acquired and the acquiring party controls a competing program. Amendment Pursuant to the terms of the Amendment, the GITR and OX40 programs immediately converted from profit-share programs to royalty-bearing programs and we became eligible to receive a flat 15% royalty on global net sales should any candidates from either of these two programs be approved. Incyte is now responsible for global development and commercialization and all associated costs for these programs. In addition, the profit-share programs relating to TIGIT and one undisclosed target were removed from the collaboration, with the undisclosed target reverting to Incyte and TIGIT to Agenus. Should any of those programs be successfully developed by a party, the other party will be eligible to receive the same milestone payments as the royalty-bearing programs and royalties at a 15% rate on global net sales. The terms for the remaining three royalty-bearing programs targeting TIM-3, LAG-3 and one undisclosed target remain unchanged, with Incyte being responsible for global development and commercialization and all associated costs. The Amendment gives Incyte exclusive rights and all decision-making authority for manufacturing, development, and commercialization with respect to all royalty-bearing programs. In connection with the Amendment, Incyte paid us $20.0 million in accelerated milestones related to the clinical development of the antibody candidates targeting GITR and OX40. Immediately following the Amendment, we were eligible to receive up to an additional $510.0 million in future potential development, regulatory and commercial milestones across all programs in the collaboration, of which $5.0 million was recognized in the quarter ended June 30, 2018. In February 2017, we also entered into a Stock Purchase Agreement with Incyte, pursuant to which Incyte purchased 10 million shares of our common stock at a purchase price of $6.00 per share. Collaboration Revenue We identified the following performance obligations under the Incyte Collaboration Agreement, as amended: (1) combined license and related research and development (“R&D”) services to a GITR antibody, (2) combined license and related R&D services to an OX40 antibody, (3) combined license and related R&D services to a TIM-3 antibody, (4) combined license and related R&D services to a LAG-3 antibody, (5) combined license and related R&D services to a TIGIT antibody, (6) combined license and related R&D services to a first undisclosed target, (7) combined license and related R&D services to a second undisclosed target, and (8) the option to license certain other mutually agreed-upon antibodies combined with related R&D Services (“Assumed Project Options Development”). Each of these performance obligations consists of a license or option to a license and related R&D services through the filing of an IND for each antibody candidate. We concluded that the licenses could be used with other readily available resources if the know-how was also transferred with the license; however, our knowledge and experience is necessary for further development of the licensed antibodies. Therefore, we determined that each of the licensed antibodies and the related developmental R&D services should be treated as a combined performance obligation. We also evaluated whether the Assumed Project Options Development was a material right. At contract inception Incyte paid us a nonrefundable access fee for the ability to exercise the option and bring additional targets into the program. Both we and Incyte have the ability to explore targets and, if mutually agreed upon, convert those targets into assumed projects for no additional license fee. We concluded that Assumed Project Options Development represents a material right and is therefore a performance obligation. We determined that there were no significant financing components, noncash consideration, or amounts that may be refunded to the customer, and as such the total upfront fixed consideration of the $10.0 million license fee and $15.0 million project access fee would be included in the total transaction price of $25.0 million. This amount was then allocated to the performance obligations on a relative stand-alone selling price basis. The estimated variable consideration to be recognized for developmental R&D services and related reimbursable expenses (“Development Costs”) was determined based on the forecasted amounts in the research plan that had been approved by the both parties via the joint steering committee (“JSC”). Under the Agreement, Development Costs related to Profit-Sharing products are split equally between us and Incyte. Therefore, our expected revenue is 50% of the costs of these programs. Based on review of the budgets presented at the JSC meetings, as well as costs of previous R&D projects, we expected the total development costs over the term of the contract would be $43.4 million. This amount was allocated entirely to the distinct R&D services that forms part of each performance obligation. We determined that the transaction price of the Collaboration Agreement was $73.7 million as of June 30, 2018, an increase of $5.3 million from the transaction price of $68.4 million as of December 31, 2017. In order to determine the transaction price, we evaluated all the payments to be received during the duration of the contract. We determined that the fixed upfront license fee and project access fee of $10.0 million and $15.0 million, respectively, and the $48.7 million of actual and estimated variable consideration for development costs (including R&D services) and milestones constituted consideration to be included in the transaction price, which is allocated among the performance obligations. For payments made to Incyte related to their work performed on profit-sharing programs, we considered that we will receive a benefit through the performance of a series of distinct R&D services by Incyte. Additionally, the R&D services are being provided by Incyte at fair value. Therefore, the amount paid to Incyte represents the fair value of the services performed, and no excess will be allocated as a reduction of the transaction price. We will record the consideration paid to Incyte in the same manner that we would purchases for other vendors, classified as R&D expense. In summary, each of the performance obligations includes a license or option to a license, and respective R&D services that will be performed over time from program initiation through the filing of an IND with respect to each antibody candidate. We have determined that the combined performance obligation is satisfied over time, and that the input method should be applied for all performance obligations that have consideration allocated to them. The cost-cost measure will be applied based on the percentage of completion of R&D services provided during the period compared to the respective budget. We believe this is the best measure of progress because other measures do not reflect how we transfer our performance obligation to Incyte. We will recognize the fixed consideration allocated to each performance obligation over time as the related R&D services are being performed using the input of R&D costs incurred over total R&D costs expected to be incurred through IND filing, beginning on the date a license is granted. A cost-based input method of revenue recognition requires management to make estimates of costs to complete our performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete our performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods. We considered the nature of the arrangement between Incyte and us in evaluating the classification of the payments to be received under the cost-sharing arrangement. We do not currently have any commercial products available for sale. Our primary operations to date have included research and development activities, licensing intellectual property and performing R&D services for external parties. Accordingly, arrangements such as this Collaboration Agreement represent our ongoing business operations. Therefore, we have concluded that payments received from Incyte under the cost-sharing arrangement represent payments made to us as part of our on-going operations and should be classified as revenue as such amounts are earned. For the three months ended June 30, 2018, we recognized approximately $6.5 million of research and development revenue. This amount included $0.3 million of the transaction price for the Collaboration Agreement recognized based on proportional performance, $5.0 million for the achievement of a milestone and $1.1 million for research and development services. For the three months ended June 30, 2017, we recognized approximately $3.9 million of research and development revenue. For the six months ended June 30, 2018, we recognized approximately $8.1 million of license and collaboration revenue. This amount included $0.8 million of the transaction price for the Collaboration Agreement recognized based on proportional performance, $5.0 million for the achievement of a milestone and $2.3 million for research and development services. For the six months ended June 30, 2017, we recognized approximately $30.8 million of research and development revenue. We expect to recognize deferred research and development revenue of $0.6 million, $0.8 million, and $1.2 million for the remainder of 2018, 2019, and 2020, respectively, related to performance obligations that are unsatisfied or partially unsatisfied as of June 30, 2018. These amounts exclude amounts (milestones, R&D services and royalties) where we have a right to invoice the customer in the amount that corresponds directly with the value of the performance completed to date. The cumulative impact of the adoption of ASC 606 for the Incyte Collaboration Agreement as of January 1, 2018 was a decrease to stockholders' deficit of approximately $6.4 million and a corresponding decrease in deferred revenue of $6.4 million. Disaggregation of Revenue The following table presents revenue (in thousands) for the three and six months ended June 30, 2018 disaggregated by geographic region and revenue type. Revenue by geographic region is allocated based on the domicile of our respective business operations. Three months ended June 30, 2018 United States Europe Total Revenue Type Research and development services $ 1,144 $ — $ 1,144 License and collaboration milestones 5,000 4,000 9,000 Recognition of deferred revenue 329 — 329 Non-cash royalty revenue 5,422 — 5,422 $ 11,895 $ 4,000 $ 15,895 Six months ended June 30, 2018 Revenue Type Research and development services $ 2,307 $ — $ 2,307 License and collaboration milestones 5,000 4,000 9,000 Recognition of deferred revenue 802 — 802 Non-cash royalty revenue 5,422 — 5,422 $ 13,531 $ 4,000 $ 17,531 Contract Balances Contract assets primarily relate to our rights to consideration for work completed in relation to our R&D services performed but not billed at the reporting date. The contract assets are transferred to the receivables when the rights become unconditional. Currently, we do not have any contract assets which have not transferred to a receivable. We had no asset impairment charges related to contract assets in the period. The contract liabilities primarily relate to contracts where we received payments but have not yet satisfied the related performance obligations. The advance consideration received from customers for R&D services or licenses bundled with other promises is a contract liability until the underlying performance obligations are transferred to the customer. The following table provides information about contract assets and contract liabilities from contracts with customers (in thousands): Six months ended June 30, 2018 Balance at beginning of period Additions Deductions Balance at end of period Contract assets: Unbilled receivables from collaboration partners $ - $ - $ - $ - Contract liabilities: Deferred revenue $ 3,377 $ - $ (802 ) $ 2,575 The change in contract liabilities is primarily related to the recognition of $0.8 million of revenue during the six months ended June 30, 2018. Deferred revenue related to our Collaboration Agreement with Incyte of $2.6 million as of June 30, 2018, which was comprised of the $25.0 million upfront payment, less $22.4 million of license and collaboration revenue recognized from the effective date of the contract, will be recognized as the combined performance obligation is satisfied. We also recorded a $10.9 million receivable as of June 30, 2018 that consisted of $1.9 million for R&D services provided and $9.0 million for the probable achievement of milestones. During the three and six months ended June 30, 2018, we did not recognize any revenue from amounts included in the contract asset or the contract liability balances from performance obligations satisfied in previous periods. None of the costs to obtain or fulfill the contract were capitalized.

Share-Based Compensation Plans

Share-Based Compensation Plans	6 Months Ended
	Jun. 30, 2018
Share Based Compensation [Abstract]
Share-Based Compensation Plans	Note K - Share-based Compensation Plans We primarily use the Black-Scholes option pricing model to value stock options granted to employees and non-employees, including stock options granted to members of our Board of Directors. All stock options have 10-year terms and generally vest ratably over a 3 or 4-year period. A non-cash charge to operations for the stock options granted to non-employees that have vesting or other performance criteria is affected each reporting period, until the non-employee options vest, by changes in the fair value of our common stock. A summary of option activity for the six months ended June 30, 2018 is presented below: Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (in years) Aggregate Intrinsic Value Outstanding at December 31, 2017 14,366,787 $ 4.22 Granted 3,795,918 5.46 Exercised (272,493 ) 3.41 Forfeited (610,260 ) 4.09 Expired (219,205 ) 5.26 Outstanding at June 30, 2018 17,060,747 $ 4.50 7.38 $ 357 Vested or expected to vest at June 30, 2018 17,060,747 $ 4.50 7.38 $ 357 Exercisable at June 30, 2018 9,751,852 $ 4.31 6.10 $ 357 The weighted average grant-date fair values of stock options granted during the six months ended June 30, 2018 and 2017 were $1.29 and $1.94, respectively. As of June 30, 2018, $10.7 million of total unrecognized compensation cost related to stock options granted to employees and directors is expected to be recognized over a weighted average period of 2.4 years. As of June 30, 2018, unrecognized expense for options granted to outside advisors for which performance (vesting) has not yet been completed but the exercise price of the option is known is $0.8 million. Such amount is subject to change each reporting period based upon changes in the fair value of our common stock, expected volatility, and the risk-free interest rate, until the outside advisor completes his or her performance under the option agreement. Certain employees and consultants have been granted non-vested stock. The fair value of non-vested market-based awards is calculated based on a Monte Carlo simulation as of the date of issuance. The fair value of other non-vested stock is calculated based on the closing sale price of our common stock on the date of issuance. A summary of non-vested stock activity for the six months ended June 30, 2018 is presented below: Non-vested Shares Weighted Average Grant Date Fair Value Outstanding at December 31, 2017 1,313,550 $ 2.91 Granted 791,829 4.08 Vested (53,050 ) 3.77 Forfeited (41,250 ) 4.30 Outstanding at June 30, 2018 2,011,079 $ 3.32 As of June 30, 2018, there was approximately $3.3 million of unrecognized share-based compensation expense related to these non-vested shares for which, if all milestones are achieved, will be recognized over a period of 2.7 years. The total intrinsic value of shares vested during the six months ended June 30, 2018, was $0.2 million. During the six months ended June 30, 2018, 47,698 shares were issued under the 2009 Employee Stock Purchase Plan, 53,050 shares were issued as a result of the vesting of non-vested stock and 272,493 shares were issued as a result of stock option exercises. The impact on our results of operations from share-based compensation for the three and six months ended June 30, 2018 and 2017, was as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Research and development $ 641 $ 1,272 $ 1,640 $ 2,399 General and administrative 944 1,480 2,150 2,730 Total share-based compensation expense $ 1,585 $ 2,752 $ 3,790 $ 5,129

Benefit Plans

Benefit Plans	6 Months Ended
	Jun. 30, 2018
Compensation And Retirement Disclosure [Abstract]
Benefit Plans	Note L - Benefit Plans Previously, we maintained a multiple employer benefit plan that covered certain international employees. During the year ended December 31, 2017, in connection with the closure of our facility in Basel, Switzerland, we ended our participation in the plan. We made no contributions to the plan during the three and six months ended June 30, 2018, and no future contributions are expected. For the three and six months ended June 30, 2017 we contributed approximately $41,000 and $83,000 to our international multiple employer benefit plan.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	6 Months Ended
	Jun. 30, 2018
New Accounting Pronouncements And Changes In Accounting Principles [Abstract]
Recent Accounting Pronouncements	Note M - Recent Accounting Pronouncements Recently Issued and Adopted In May 2014, the FASB issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers, (Topic 606) ("ASU 2014-09"). ASU 2014-09 amends the guidance for the recognition of revenue from contracts with customers to transfer goods and services. The FASB subsequently issued additional, clarifying standards to address issues arising from the implementation of the new revenue recognition standard. The new revenue recognition standard and clarifying standards require an entity to recognize revenue when control of promised goods or services is transferred to the customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. We adopted this new standard on January 1, 2018, by using the modified-retrospective method. See Note B and Note J. In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business (“ASU 2017-01”), which provides guidance regarding the definition of a business, with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. We adopted ASU 2017-01 on January 1, 2018 and will apply it prospectively. The impact on our consolidated financial statements in future periods will depend on the specific facts and circumstances of future transactions. In May 2017, the FASB issued ASU No. 2017-09, Compensation – Stock Compensation (Topic 718) Scope of Modification Accounting (“ASU 2017-09”). The amendments in ASU 2017-09 provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. We adopted ASU 2017-09 on January 1, 2018. The guidance will be applied prospectively to awards modified on or after the adoption date. The adoption of ASU 2017-09 did not have any impact on our consolidated financial statements. Recently Issued, Not Yet Adopted In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) (“ASU 2016-02”) which supersedes Topic 840, Leases. ASU 2016-02 requires lessees to recognize a right-of-use asset and a lease liability on their balance sheets for all leases with terms greater than twelve months. Based on certain criteria, leases will be classified as either financing or operating, with classification affecting the pattern of expense recognition in the income statement. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. If a lessee makes this election, it should recognize lease expense for such leases generally on a straight-line basis over the lease term. ASU 2016-2 is effective for fiscal years beginning after December 15, 2018, and interim periods within those years, with early adoption permitted. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. The modified retrospective approach includes a number of optional practical expedients primarily focused on leases that commenced before the effective date of Topic 842, including continuing to account for leases that commence before the effective date in accordance with previous guidance, unless the lease is modified. In July 2018, the FASB issued ASU 2018-11, which provides companies an additional, optional, transition method. This optional method allows companies to initially apply the standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Note 15 in our Annual Report on Form 10-K for the year ended December 31, 2017 provides details on our current lease arrangements. While we continue to evaluate the provisions of ASC 842 to determine how it will be affected, the primary effect of adopting the new standard will be to record assets and obligations for current operating leases. Upon adoption, based on leases in place as of December 31, 2017, we expect to recognize assets and liabilities of approximately $8.2 million related to our operating leases. The adoption of ASC 842 is not expected to have a material impact on our results of operations or cash flows. In January 2017, the FASB issued ASU 2017-04, Intangibles – Goodwill and Other (Topic 350) (“ASU 2017-04”) that will eliminate the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment charge. Instead, an impairment charge will be based on the excess of a reporting unit’s carrying amount over its fair value. The guidance is effective for the Company in the first quarter of fiscal 2020. Early adoption is permitted. We do not anticipate the adoption of this guidance to have a material impact on our consolidated financial statements, absent any goodwill impairment. In June 2018, the FASB issued ASU No. 2018-07, Compensation – Stock Compensation (Topic 718) Improvements to Nonemployee Share-Based Payment Accounting (“ASU 2018-07”). The amendments in ASU 2018-07 simplify the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The standard will be effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years, with early adoption permitted. We are currently evaluating the impact of adoption of ASU 2018-07 on our consolidated financial statements. No other new accounting pronouncement issued or effective during the six months ended June 30, 2018 had or is expected to have a material impact on our consolidated financial statements or disclosures.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2018
Subsequent Events [Abstract]
Subsequent Events	Note N - Subsequent Events At the Market Offerings In July and August 2018, we received aggregate net proceeds of approximately $4.2 million from the sale of approximately 2.2 million shares of our common stock in at-the-market offerings under our At Market Issuance Sales Agreement with B. Riley FBR, Inc. As of August 9, 2018, approximately 10.6 million shares remain available for sale under this agreement.

Summary of Significant Accoun21

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Revenue	Revenue In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes existing revenue recognition guidance. We adopted ASU 2014-09 and its related amendments (collectively known as “ASC 606”) on January 1, 2018 using the modified retrospective method- i.e., by recognizing the cumulative effect of initially applying ASC 606 as an adjustment to the opening balance of equity at January 1, 2018. The reported results for 2018 reflect the application of ASC 606 guidance while the reported results for 2017 were prepared under the guidance of ASC 605, Revenue Recognition (“ASC 605”). The adoption of ASC 606 represents a change in accounting principle that will more closely align revenue recognition with the delivery of our goods and services and will provide financial statement readers with enhanced disclosures. The details of the significant changes and quantitative impact of the changes are disclosed in Note J. In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which we expect to be entitled to receive in exchange for these goods and services. To achieve this core principle, we apply the following five steps: 1) Identify the contract with the customer A contract with a customer exists when (i) the Company enters into an enforceable contract with a customer that defines each party’s rights regarding the goods or services to be transferred and identifies the related payment terms, (ii) the contract has commercial substance, and (iii) the Company determines that collection of substantially all consideration for goods and services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration. The Company applies judgment in determining the customer’s intent and ability to pay, which is based on a variety of factors including the customer’s historical payment experience, or in the case of a new customer, published credit and financial information pertaining to the customer. 2) Identify the performance obligations in the contract Performance obligations promised in a contract are identified based on the goods and services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the good or service either on its own or together with other available resources, and are distinct in the context of the contract, whereby the transfer of the good or service is separately identifiable from other promises in the contract. To the extent a contract includes multiple promised goods and services, the Company must apply judgment to determine whether promised goods and services are capable of being distinct and are distinct in the context of the contract. If these criteria are not met, the promised goods and services are accounted for as a combined performance obligation. 3) Determine the transaction price The transaction price is determined based on the consideration to which the Company will be entitled in exchange for transferring goods and services to the customer. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing either the expected value method or the most likely amount method depending on the nature of the variable consideration. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Any estimates, including the effect of the constraint on variable consideration, are evaluated at each reporting period for any changes. Determining the transaction price requires significant judgment, which is discussed in further detail for each of the Company’s contracts with customers in Note J. 4) Allocate the transaction price to performance obligations in the contract If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation on a relative stand-alone selling price basis unless the transaction price is variable and meets the criteria to be allocated entirely to a performance obligation or to a distinct service that forms part of a single performance obligation. The consideration to be received is allocated among the separate performance obligations based on relative stand-alone selling prices. Determining the amount of the transaction price to allocate to each separate performance obligation requires significant judgement, which is discussed in further detail for each of the Company’s contracts with customers in Note J. 5) Recognize revenue when or as the Company satisfies a performance obligation The Company satisfies performance obligations either over time or at a point in time. Revenue is recognized over time if either 1) the customer simultaneously receives and consumes the benefits provided by the entity’s performance, 2) the entity’s performance creates or enhances an asset that the customer controls as the asset is created or enhanced, or 3) the entity’s performance does not create an asset with an alternative use to the entity and the entity has an enforceable right to payment for performance completed to date. If the entity does not satisfy a performance obligation over time, the related performance obligation is satisfied at a point in time by transferring the control of a promised good or service to a customer. Examples of control are using the asset to produce goods or services, enhance the value of other assets, settle liabilities, and holding or selling the asset. ASC 606 requires the Company to select a single revenue recognition method for the performance obligation that faithfully depicts the Company’s performance in transferring control of the goods and services. The guidance allows entities to choose between two methods to measure progress toward complete satisfaction of a performance obligation: 1. Output methods - recognize revenue on the basis of direct measurements of the value to the customer of the goods or services transferred to date relative to the remaining goods or services promised under the contract (e.g. surveys of performance completed to date, appraisals of results achieved, milestones reached, time elapsed, and units of produced or units delivered); and 2. Input methods - recognize revenue on the basis of the entity’s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation. Licenses of intellectual property: If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Milestone payments: At the inception of each arrangement that includes development, regulatory or commercial milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. Whichever method is used, it should be consistently applied throughout the life of the contract; however, it is not necessary for the Company to use the same approach for all contracts. The Company uses the most likely amount method for development and regulatory milestone payments. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. Royalties: For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Up-front Fees: Depending on the nature of the agreement, up-front payments and fees may be recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company’s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less. Impact of Adopting ASC 606 on Financial Statements We adopted ASC 606 using the modified retrospective method. The cumulative effect of applying the new guidance to all contracts with customers that were not completed as of January 1, 2018 was recorded as an adjustment to accumulated deficit as of the adoption date. We elected to apply a practical expedient to reflect the aggregate effect of all modifications that occurred before January 1, 2018 when identifying the satisfied and unsatisfied performance obligations, determining the transaction price, and allocating the transaction price to the satisfied and unsatisfied performance obligations. The estimated effect of applying this practical expedient results in a slower recognition of the transaction price, as more consideration is allocated to performance obligations originally identified as a material right at contract inception. As a result of applying the modified retrospective method to adopt the new revenue guidance, the following adjustments were made to the consolidated balance sheet as of January 1, 2018 (in thousands): As Reported December 31, 2017 ASC 606 Adjustment Adjusted January 1, 2018 Consolidated Balance Sheet Data: Current portion, deferred revenue $ 4,485 $ (2,986 ) $ 1,499 Deferred revenue, net of current portion 7,748 (5,870 ) 1,878 Accumulated deficit $ (1,026,476 ) $ 8,856 $ (1,017,620 ) Impact of ASC 606 on Financial Statements In accordance with Topic 606, the disclosure of the impact of adoption to our condensed consolidated statements of income and balance sheets was as follows (in thousands): Six months ended June 30, 2018 As Reported Under ASC 606 Adjustments Notes Balances without Adoption of ASC 606 Consolidated Balance Sheet Data: Accounts receivable $ 10,920 $ (4,000 ) (1 ) $ 6,920 Current portion, deferred revenue 947 942 (2 ) 1,889 Deferred revenue, net of current portion 1,628 5,176 (2 ) 6,804 Accumulated deficit (1,096,431 ) (10,118 ) (3 ) (1,106,549 ) Consolidated Statement of Operations Data: Research and development revenue $ 12,109 $ (1,261 ) (4 ) $ 10,848 Three months ended June 30, 2018 Consolidated Statement of Operations Data: Research and development revenue $ 10,473 $ (1,842 ) (4 ) $ 8,631 (1) Adjustment to accounts receivable to reflect a milestone recognized under ASC 606 and included in accounts receivable on June 30, 2018. (2) Adjustment to deferred revenue to reflect recognition of revenue under ASC 605 primarily attributable to the change in the timing of revenue recognition for amounts received under the Incyte Collaboration Agreement, see Note J. (3) Adjustment to accumulated deficit to reflect the reversal of the cumulative transition adjustment and the difference in revenue from ASC 606 to ASC 605, see Note J. (4) Adjustment to reflect the difference in revenue recognition from ASC 606 to ASC 605 primarily attributable to the recognition of a milestone under ASC 606 that was partially offset by the change in recognition of an upfront fee related to the GSK License and Amended Supply Agreements, see Note J.
Net Loss Per Share	Note C - Net Loss Per Share Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding (including common shares issuable under our Directors’ Deferred Compensation Plan, or “DDCP”). Diluted income per common share is calculated by dividing net income attributable to common stockholders by the weighted average number of common shares outstanding (including common shares issuable under our DDCP) plus the dilutive effect of outstanding instruments such as warrants, stock options, non-vested shares, convertible preferred stock, and convertible notes. Because we reported a net loss attributable to common stockholders for all periods presented, diluted loss per common share is the same as basic loss per common share, as the effect of utilizing the fully diluted share count would have reduced the net loss per common share. Therefore, the following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding as of June 30, 2018 and 2017, as they would be anti-dilutive: Three and Six Months Ended June 30, 2018 2017 Warrants 2,900,000 4,351,450 Stock options 17,060,747 15,287,781 Non-vested shares 2,011,079 2,022,324 Convertible preferred stock 333,333 333,333

Business, Liquidity and Basis22

Business, Liquidity and Basis of Presentation (Tables)	6 Months Ended
	Jun. 30, 2018
Description Of Business [Abstract]
Schedule of Cash and Cash Equivalents	The following table outlines our quarter end cash and cash equivalents balances and the changes therein (in millions). Quarter Ended March 31, 2018 June 30, 2018 Cash and cash equivalents $ 52.3 $ 43.2 Decrease in cash and cash equivalents $ (7.8 ) $ (9.2 ) Cash used in operating activities $ (40.2 ) $ (30.5 ) Reported net loss $ (54.3 ) $ (25.2 )

Summary of Significant Accoun23

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2018
Topic 606 [Member]
Topic 606 Disclosure of Impact of Adoption to Condensed Consolidated Statements	As a result of applying the modified retrospective method to adopt the new revenue guidance, the following adjustments were made to the consolidated balance sheet as of January 1, 2018 (in thousands): As Reported December 31, 2017 ASC 606 Adjustment Adjusted January 1, 2018 Consolidated Balance Sheet Data: Current portion, deferred revenue $ 4,485 $ (2,986 ) $ 1,499 Deferred revenue, net of current portion 7,748 (5,870 ) 1,878 Accumulated deficit $ (1,026,476 ) $ 8,856 $ (1,017,620 ) In accordance with Topic 606, the disclosure of the impact of adoption to our condensed consolidated statements of income and balance sheets was as follows (in thousands): Six months ended June 30, 2018 As Reported Under ASC 606 Adjustments Notes Balances without Adoption of ASC 606 Consolidated Balance Sheet Data: Accounts receivable $ 10,920 $ (4,000 ) (1 ) $ 6,920 Current portion, deferred revenue 947 942 (2 ) 1,889 Deferred revenue, net of current portion 1,628 5,176 (2 ) 6,804 Accumulated deficit (1,096,431 ) (10,118 ) (3 ) (1,106,549 ) Consolidated Statement of Operations Data: Research and development revenue $ 12,109 $ (1,261 ) (4 ) $ 10,848 Three months ended June 30, 2018 Consolidated Statement of Operations Data: Research and development revenue $ 10,473 $ (1,842 ) (4 ) $ 8,631 (1) Adjustment to accounts receivable to reflect a milestone recognized under ASC 606 and included in accounts receivable on June 30, 2018. (2) Adjustment to deferred revenue to reflect recognition of revenue under ASC 605 primarily attributable to the change in the timing of revenue recognition for amounts received under the Incyte Collaboration Agreement, see Note J. (3) Adjustment to accumulated deficit to reflect the reversal of the cumulative transition adjustment and the difference in revenue from ASC 606 to ASC 605, see Note J. (4) Adjustment to reflect the difference in revenue recognition from ASC 606 to ASC 605 primarily attributable to the recognition of a milestone under ASC 606 that was partially offset by the change in recognition of an upfront fee related to the GSK License and Amended Supply Agreements, see Note J.

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2018
Earnings Per Share [Abstract]
Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Weighted Average Shares Outstanding	the following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding as of June 30, 2018 and 2017, as they would be anti-dilutive: Three and Six Months Ended June 30, 2018 2017 Warrants 2,900,000 4,351,450 Stock options 17,060,747 15,287,781 Non-vested shares 2,011,079 2,022,324 Convertible preferred stock 333,333 333,333

Investments (Tables)

Investments (Tables)	6 Months Ended
	Jun. 30, 2018
Cash And Cash Equivalents [Abstract]
Schedule of Cash Equivalents	Cash equivalents consisted of the following as of June 30, 2018 and December 31, 2017 (in thousands): June 30, 2018 December 31, 2017 Cost Estimated Fair Value Cost Estimated Fair Value Institutional money market funds $ 39,372 $ 39,372 $ 57,036 $ 57,036

Goodwill and Acquired Intangi26

Goodwill and Acquired Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2018
Goodwill And Intangible Assets Disclosure [Abstract]
Schedule of Changes in Goodwill	The following table sets forth the changes in the carrying amount of goodwill for the six months ended June 30, 2018 (in thousands): Balance, December 31, 2017 $ 23,049 Foreign currency translation adjustment (235 ) Balance, June 30, 2018 $ 22,814
Schedule of Acquired Intangible Assets	Acquired intangible assets consisted of the following as of June 30, 2018 and December 31, 2017 (in thousands): As of June 30, 2018 Amortization period (years) Gross carrying amount Accumulated amortization Net carrying amount Intellectual property 7-15 years $ 16,478 $ (5,205 ) $ 11,273 Trademarks 4.5 years 814 (791 ) 23 Other 2-6 years 568 (481 ) 87 In-process research and development Indefinite 1,898 — 1,898 Total $ 19,758 $ (6,477 ) $ 13,281 As of December 31, 2017 Amortization period (years) Gross carrying amount Accumulated amortization Net carrying amount Intellectual property 7-15 years $ 16,545 $ (4,290 ) $ 12,255 Trademarks 4.5 years 826 (711 ) 115 Other 2-6 years 570 (461 ) 109 In-process research and development Indefinite 1,928 — 1,928 Total $ 19,869 $ (5,462 ) $ 14,407

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jun. 30, 2018
Debt Disclosure [Abstract]
Schedule of Debt Obligations	Debt obligations consisted of the following as of June 30, 2018 and December 31, 2017 (in thousands): Debt instrument Principal at June 30, 2018 Non-cash Interest Unamortized Debt Issuance Costs Unamortized Debt Discount Balance at June 30, 2018 Current Portion: Debentures $ 146 $ — $ — $ — $ 146 Long-term Portion: 2015 Subordinated Notes 14,000 — — (1,093 ) 12,907 Total $ 14,146 $ — $ — $ (1,093 ) $ 13,053 Debt instrument Principal at December 31, 2017 Non-cash Interest Unamortized Debt Issuance Costs Unamortized Debt Discount Balance at December 31, 2017 Current Portion: Debentures $ 146 $ — $ — $ — $ 146 Note Purchase Agreement 15,000 5,494 — — 20,494 Total current 15,146 5,494 — — 20,640 Long-term Portion: 2015 Subordinated Notes 14,000 — — (1,375 ) 12,625 Note Purchase Agreement 100,000 31,323 (1,362 ) (201 ) 129,760 Total long-term 114,000 31,323 (1,362 ) (1,576 ) 142,385 Total $ 129,146 $ 36,817 $ (1,362 ) $ (1,576 ) $ 163,025

Liability Related to the Sale28

Liability Related to the Sale of Future Royalties (Tables)	6 Months Ended
	Jun. 30, 2018
Liability Related To Sale Of Future Royalties [Abstract]
Schedule of Liability Account from Inception of Royalty Agreement	The following table shows the activity within the liability account from the inception of the royalty agreement in January 2018 to June 30, 2018 (in thousands): Period from inception to June 30, 2018 Liability related to sale of future royalties - beginning balance $ — Proceeds from sale of future royalties 190,000 Non-cash royalty revenue (5,422 ) Non-cash interest expense recognized 7,565 Liability related to sale of future royalties - ending balance 192,143 Less: unamortized transaction costs (565 ) Liability related to sale of future royalties, net $ 191,578

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2018
Other Liabilities Disclosure [Abstract]
Schedule of Accrued Liabilities	Accrued liabilities consisted of the following as of June 30, 2018 and December 31, 2017 (in thousands): June 30, 2018 December 31, 2017 Payroll $ 4,920 $ 7,790 Professional fees 2,988 2,021 Contract manufacturing costs 5,339 5,528 Research services 6,653 4,663 Other 1,092 1,567 Total $ 20,992 $ 21,569

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2018
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value	Liabilities measured at fair value are summarized below (in thousands): Description June 30, 2018 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Liabilities: Contingent purchase price considerations $ 3,097 $ — $ — $ 3,097 Total $ 3,097 $ — $ — $ 3,097 Description December 31, 2017 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Liabilities: Contingent purchase price consideration $ 4,373 $ — $ — $ 4,373 Total $ 4,373 $ — $ — $ 4,373
Schedule of Liabilities Measured at Fair Value Using Significant Unobservable Inputs	The following table presents our liabilities measured at fair value using significant unobservable inputs (Level 3), as of June 30, 2018 (in thousands): Balance, December 31, 2017 $ 4,373 Change in fair value of contingent purchase price considerations during the period (1,276 ) Balance, June 30, 2018 $ 3,097

Revenue from Contracts with C31

Revenue from Contracts with Customers (Tables)	6 Months Ended
	Jun. 30, 2018
Collaboration [Abstract]
Summary of Disaggregation of Revenue	The following table presents revenue (in thousands) for the three and six months ended June 30, 2018 disaggregated by geographic region and revenue type. Revenue by geographic region is allocated based on the domicile of our respective business operations. Three months ended June 30, 2018 United States Europe Total Revenue Type Research and development services $ 1,144 $ — $ 1,144 License and collaboration milestones 5,000 4,000 9,000 Recognition of deferred revenue 329 — 329 Non-cash royalty revenue 5,422 — 5,422 $ 11,895 $ 4,000 $ 15,895 Six months ended June 30, 2018 Revenue Type Research and development services $ 2,307 $ — $ 2,307 License and collaboration milestones 5,000 4,000 9,000 Recognition of deferred revenue 802 — 802 Non-cash royalty revenue 5,422 — 5,422 $ 13,531 $ 4,000 $ 17,531
Schedule of Information about Contract Assets and Contract Liabilities from Contracts with Customers	The following table provides information about contract assets and contract liabilities from contracts with customers (in thousands): Six months ended June 30, 2018 Balance at beginning of period Additions Deductions Balance at end of period Contract assets: Unbilled receivables from collaboration partners $ - $ - $ - $ - Contract liabilities: Deferred revenue $ 3,377 $ - $ (802 ) $ 2,575

Share-Based Compensation Plans

Share-Based Compensation Plans (Tables)	6 Months Ended
	Jun. 30, 2018
Share Based Compensation [Abstract]
Schedule Of Stock Option Activity	A summary of option activity for the six months ended June 30, 2018 is presented below: Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (in years) Aggregate Intrinsic Value Outstanding at December 31, 2017 14,366,787 $ 4.22 Granted 3,795,918 5.46 Exercised (272,493 ) 3.41 Forfeited (610,260 ) 4.09 Expired (219,205 ) 5.26 Outstanding at June 30, 2018 17,060,747 $ 4.50 7.38 $ 357 Vested or expected to vest at June 30, 2018 17,060,747 $ 4.50 7.38 $ 357 Exercisable at June 30, 2018 9,751,852 $ 4.31 6.10 $ 357
Summary Of Non-vested Stock Activity	A summary of non-vested stock activity for the six months ended June 30, 2018 is presented below: Non-vested Shares Weighted Average Grant Date Fair Value Outstanding at December 31, 2017 1,313,550 $ 2.91 Granted 791,829 4.08 Vested (53,050 ) 3.77 Forfeited (41,250 ) 4.30 Outstanding at June 30, 2018 2,011,079 $ 3.32
Schedule Of Share-Based Compensation Expense	The impact on our results of operations from share-based compensation for the three and six months ended June 30, 2018 and 2017, was as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Research and development $ 641 $ 1,272 $ 1,640 $ 2,399 General and administrative 944 1,480 2,150 2,730 Total share-based compensation expense $ 1,585 $ 2,752 $ 3,790 $ 5,129

Business, Liquidity and Basis33

Business, Liquidity and Basis of Presentation (Narrative) (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Description Of Business [Abstract]
Cash and cash equivalents	$ 43,163,886	$ 52,300,000	$ 43,163,886	$ 81,829,729	$ 60,186,617	$ 71,448,016
Decrease in cash and cash equivalents	9,200,000	$ 7,800,000	17,022,731	$ (10,381,713)
Accumulated deficit	$ 1,096,430,845		$ 1,096,430,845		$ 1,026,475,773

Business, Liquidity and Basis34

Business, Liquidity and Basis of Presentation - Schedule of Cash and Cash Equivalents (Details) - USD ($)	3 Months Ended			6 Months Ended
	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Description Of Business [Abstract]
Cash and cash equivalents	$ 43,163,886	$ 52,300,000	$ 81,829,729	$ 43,163,886	$ 81,829,729	$ 60,186,617	$ 71,448,016
Decrease in cash and cash equivalents	(9,200,000)	(7,800,000)		(17,022,731)	10,381,713
Cash used in operating activities	(30,500,000)	(40,200,000)		(70,779,454)	(42,211,910)
Reported net loss	$ (25,203,780)	$ (54,300,000)	$ (31,713,042)	$ (79,464,923)	$ (48,816,220)

Summary of Significant Accoun35

Summary of Significant Accounting Policies (Topic 606 Disclosure of Impact of Adoption to Condensed Consolidated Statements) (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Jan. 01, 2018	Dec. 31, 2017
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Accounts receivable	$ 10,919,713		$ 10,919,713			$ 1,134,493
Current portion, deferred revenue	946,775		946,775			4,484,882
Deferred revenue, net of current portion	1,627,786		1,627,786			7,748,284
Accumulated deficit	(1,096,430,845)		(1,096,430,845)			$ (1,026,475,773)
Revenue	15,894,625	$ 4,207,573	17,530,666	$ 31,163,416
Research and Development Revenue [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Revenue	10,472,934	$ 4,207,573	12,108,975	$ 31,163,416
Topic 606 [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Current portion, deferred revenue					$ 1,499,000
Deferred revenue, net of current portion					1,878,000
Accumulated deficit					(1,017,620,000)
Topic 606 [Member] | ASC 606 Adjustment [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Accounts receivable	(4,000,000)		(4,000,000)
Current portion, deferred revenue	942,000		942,000		(2,986,000)
Deferred revenue, net of current portion	5,176,000		5,176,000		(5,870,000)
Accumulated deficit	(10,118,000)		(10,118,000)		$ 8,856,000
Topic 606 [Member] | ASC 606 Adjustment [Member] | Research and Development Revenue [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Revenue	(1,842,000)		(1,261,000)
Topic 606 [Member] | Balances without Adoption of ASC 606 [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Accounts receivable	6,920,000		6,920,000
Current portion, deferred revenue	1,889,000		1,889,000
Deferred revenue, net of current portion	6,804,000		6,804,000
Accumulated deficit	(1,106,549,000)		(1,106,549,000)
Topic 606 [Member] | Balances without Adoption of ASC 606 [Member] | Research and Development Revenue [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Revenue	$ 8,631,000		$ 10,848,000

Net Loss Per Share (Schedule of

Net Loss Per Share (Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Weighted Average Shares Outstanding) (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,900,000	4,351,450	2,900,000	4,351,450
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	17,060,747	15,287,781	17,060,747	15,287,781
Non-vested Shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,011,079	2,022,324	2,011,079	2,022,324
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	333,333	333,333	333,333	333,333

Investments (Schedule of Cash E

Investments (Schedule of Cash Equivalents) (Details) - Institutional Money Market Funds [Member] - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Cost [Member]
Cash And Cash Equivalents [Line Items]
Cash equivalents	$ 39,372	$ 57,036
Estimated Fair Value [Member]
Cash And Cash Equivalents [Line Items]
Cash equivalents	$ 39,372	$ 57,036

Goodwill and Acquired Intangi38

Goodwill and Acquired Intangible Assets (Schedule of Changes in Goodwill) (Details)	6 Months Ended
	Jun. 30, 2018USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 23,048,804
Foreign currency translation adjustment	(235,000)
Ending balance	$ 22,814,031

Goodwill and Acquired Intangi39

Goodwill and Acquired Intangible Assets (Acquired Intangible Assets) (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross (Excluding Goodwill)	$ 19,758,000	$ 19,869,000
Accumulated amortization	(6,476,682)	(5,461,834)
Net carrying amount	13,280,795	14,406,650
Indefinite-lived Intangible Assets Acquired	1,898,000	1,928,000
Intellectual Property [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	16,478,000	16,545,000
Accumulated amortization	(5,205,000)	(4,290,000)
Net carrying amount	$ 11,273,000	$ 12,255,000
Intellectual Property [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization period (years)	7 years	7 years
Intellectual Property [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization period (years)	15 years	15 years
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization period (years)	4 years 6 months	4 years 6 months
Gross carrying amount	$ 814,000	$ 826,000
Accumulated amortization	(791,000)	(711,000)
Net carrying amount	23,000	115,000
Other [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	568,000	570,000
Accumulated amortization	(481,000)	(461,000)
Net carrying amount	$ 87,000	$ 109,000
Other [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization period (years)	2 years	2 years
Other [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization period (years)	6 years	6 years

Goodwill and Acquired Intangi40

Goodwill and Acquired Intangible Assets (Narrative) (Details) $ in Millions	6 Months Ended
	Jun. 30, 2018USD ($)
Goodwill And Intangible Assets Disclosure [Abstract]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	9 years
Finite-Lived Intangible Assets, Estimated Amortization Expense, 2018	$ 1
Finite-Lived Intangible Assets, Estimated Amortization Expense, December 31, 2019	1.9
Finite-Lived Intangible Assets, Estimated Amortization Expense, December 31, 2020	1.9
Finite-Lived Intangible Assets, Estimated Amortization Expense, December 31, 2021	1.9
Finite-Lived Intangible Assets, Estimated Amortization Expense, December 31, 2022	$ 1.9

Debt - Schedule of Debt Obligat

Debt - Schedule of Debt Obligations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Jun. 30, 2018
Debt instrument, Current Portion
Principal Balance, Short-term Portion	$ 15,146
Non-cash Interest, Short-term Position	5,494
Balance, Short-term Portion	20,640
Debt instrument, Long-term Portion
Principal Balance, Long-term Portion	114,000
Non-cash Interest, Long-term Portion	31,323
Unamortized Debt Issuance Costs, Long-term Portion	(1,362)
Unamortized Debt Discount, Long-term Portion	(1,576)
Balance, Long-term Portion	142,385
Principal, Balance Total	129,146	$ 14,146
Non-cash Interest Total	36,817
Unamortized Debt Issuance Costs Total	(1,362)
Unamortized Debt Discount Total	(1,576)	(1,093)
Balance, Long-Term Debt Total	163,025	13,053
2015 Subordinated Notes [Member]
Debt instrument, Long-term Portion
Principal Balance, Long-term Portion	14,000	14,000
Unamortized Debt Discount, Long-term Portion	(1,375)	(1,093)
Balance, Long-term Portion	12,625	12,907
Note Purchase Agreement [Member]
Debt instrument, Long-term Portion
Principal Balance, Long-term Portion	100,000
Non-cash Interest, Long-term Portion	31,323
Unamortized Debt Issuance Costs, Long-term Portion	(1,362)
Unamortized Debt Discount, Long-term Portion	(201)
Balance, Long-term Portion	129,760
Debentures [Member]
Debt instrument, Current Portion
Principal Balance, Short-term Portion	146	146
Balance, Short-term Portion	146	$ 146
Note Purchase Agreement [Member]
Debt instrument, Current Portion
Principal Balance, Short-term Portion	15,000
Non-cash Interest, Short-term Position	5,494
Balance, Short-term Portion	$ 20,494

Debt (Narrative) (Details)

Debt (Narrative) (Details) - USD ($)	Jan. 19, 2018	Jan. 31, 2018	Jun. 30, 2018	Jun. 30, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Carrying value of capital lease included in property, plant and equipment, net			$ 26,922,101	$ 26,922,101	$ 26,178,622
Consideration received for royalty rights			190,000,000
Payments of debt				161,847,223
Loss on early extinguishment of debt				$ (10,766,625)
HCR [Member] | GSK Agreements [Member] | Royalty Purchase Agreement [Member]
Debt Instrument [Line Items]
Consideration received for royalty rights	$ 190,000,000
Equipment [Member]
Debt Instrument [Line Items]
Capital lease expiration period				2,020
Payment to lessor, remainder of 2018			190,000	$ 190,000
Payment to lessor, 2019			375,000	375,000
Payment to lessor, 2020			165,000	165,000
Capital lease obligations			700,000	700,000
Equipment [Member] | Other Current Liabilities [Member]
Debt Instrument [Line Items]
Capital lease obligations included in other current liabilities			360,000	360,000
Equipment [Member] | Other Long-term Liabilities [Member]
Debt Instrument [Line Items]
Capital lease obligations included in other long-term liabilities			330,000	330,000
Capital Lease [Member] | Equipment [Member]
Debt Instrument [Line Items]
Carrying value of capital lease included in property, plant and equipment, net			$ 1,000,000	$ 1,000,000
Note Purchase Agreement [Member] | Oberland Capital SA Zermatt LLC [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	115,000,000
Payments of debt	$ 161,900,000
Loss on early extinguishment of debt		$ 10,800,000

Liability Related to the Sale43

Liability Related to the Sale of Future Royalties (Narrative) (Details) - USD ($)	Jan. 19, 2018	Jan. 06, 2018	Jun. 30, 2018	Jun. 30, 2018	Jun. 30, 2018
Liability Related To Sale Of Future Royalties [Line Items]
Gross proceeds received for royalty rights				$ 190,000,000
Non-cash royalty revenue recognized				5,422,000
Non-cash interest expense				$ 7,565,000
GSK Agreements [Member]
Liability Related To Sale Of Future Royalties [Line Items]
Non-cash royalty revenue recognized			$ 5,400,000		$ 5,400,000
HCR [Member] | GSK Agreements [Member]
Liability Related To Sale Of Future Royalties [Line Items]
Effective annual interest rate			12.00%
Prospective effective annual interest rate			12.20%
HCR [Member] | GSK Agreements [Member] | Royalty Purchase Agreement [Member]
Liability Related To Sale Of Future Royalties [Line Items]
Percentage of purchase of worldwide rights to receive royalties		100.00%
Gross proceeds received for royalty rights	$ 190,000,000
Reimbursed HCR for transaction costs	100,000
Transaction costs incurred	500,000
Non-cash royalty revenue recognized					5,400,000
Non-cash interest expense					$ 7,600,000
HCR [Member] | GSK Agreements [Member] | Royalty Purchase Agreement [Member] | Maximum [Member]
Liability Related To Sale Of Future Royalties [Line Items]
Potential milestone payments receivable	40,400,000
HCR [Member] | GSK Agreements [Member] | Royalty Purchase Agreement [Member] | Prior to 2024 [Member]
Liability Related To Sale Of Future Royalties [Line Items]
Potential milestone payments receivable	15,100,000
Sales milestones target		$ 2,000,000,000
HCR [Member] | GSK Agreements [Member] | Royalty Purchase Agreement [Member] | Prior to 2026 [Member]
Liability Related To Sale Of Future Royalties [Line Items]
Potential milestone payments receivable	$ 25,300,000
Sales milestones target		2,750,000,000
HCR [Member] | GSK Agreements [Member] | Royalty Purchase Agreement [Member] | 2021 [Member]
Liability Related To Sale Of Future Royalties [Line Items]
Payables upon not achieving sales milestones		25,900,000
HCR [Member] | GSK Agreements [Member] | Royalty Purchase Agreement [Member] | 2019 [Member]
Liability Related To Sale Of Future Royalties [Line Items]
Sales milestones target		1,000,000,000
HCR [Member] | GSK Agreements [Member] | Royalty Purchase Agreement [Member] | 2020 [Member]
Liability Related To Sale Of Future Royalties [Line Items]
Sales milestones target		$ 1,750,000,000

Liability Related to the Sale44

Liability Related to the Sale of Future Royalties (Schedule of Liability Account from Inception of Royalty Agreement) (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018
Liability Related To Sale Of Future Royalties [Abstract]
Proceeds from sale of future royalties	$ 190,000
Non-cash royalty revenue	(5,422)
Non-cash interest expense recognized	7,565
Liability related to sale of future royalties - ending balance	192,143
Less: unamortized transaction costs	(565)
Liability related to sale of future royalties, net	$ 191,578

Accrued Liabilities (Schedule o

Accrued Liabilities (Schedule of Accrued Liabilities) (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Accrued Liabilities Current [Abstract]
Payroll	$ 4,920,000	$ 7,790,000
Professional fees	2,988,000	2,021,000
Contract manufacturing costs	5,339,000	5,528,000
Research services	6,653,000	4,663,000
Other	1,092,000	1,567,000
Total	$ 20,992,107	$ 21,569,449

Fair Value Measurements (Narrat

Fair Value Measurements (Narrative) (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Contingent purchase price consideration	$ 3,097	$ 4,373
Long-term Debt, Gross	14,146	129,146
Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Contingent purchase price consideration	0	0
Debt Instrument, Fair Value Disclosure	$ 14,200	$ 205,900

Fair Value Measurements (Schedu

Fair Value Measurements (Schedule of Assets and Liabilities Measured at Fair Value) (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Contingent purchase price considerations, Fair Value Disclosure	$ 3,097	$ 4,373
Total	3,097	4,373
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Contingent purchase price considerations, Fair Value Disclosure	0	0
Total	0	0
Significant Other Observable Inputs (Level 2) [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Contingent purchase price considerations, Fair Value Disclosure	0	0
Total	0	0
Significant Unobservable Inputs (Level 3) [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Contingent purchase price considerations, Fair Value Disclosure	3,097	4,373
Total	$ 3,097	$ 4,373

Fair Value Measurements (Sche48

Fair Value Measurements (Schedule of Liabilities Measured at Fair Value Using Significant Unobservable Inputs) (Details) - Significant Unobservable Inputs (Level 3) [Member] $ in Thousands	6 Months Ended
	Jun. 30, 2018USD ($)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Balance, beginning of period	$ 4,373
Balance, end of period	3,097
Contingent purchase price [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Change in fair value of considerations during the period	$ (1,276)

Revenue from Contract with Cust

Revenue from Contract with Customers (Narrative) (Details) $ / shares in Units, shares in Thousands	Jan. 02, 2018USD ($)	Feb. 28, 2017$ / sharesshares	Feb. 14, 2017USD ($)	Nov. 30, 2015Program	Feb. 19, 2015USD ($)Program	Jan. 09, 2015USD ($)Programshares	Mar. 31, 2012USD ($)	Jul. 31, 2007USD ($)	Jul. 31, 2006USD ($)	Jun. 30, 2018USD ($)	Jun. 30, 2017USD ($)	Jun. 30, 2018USD ($)	Jun. 30, 2018USD ($)	Jun. 30, 2017USD ($)	Dec. 31, 2017USD ($)
Deferred Revenue Arrangement [Line Items]
Proceeds from Collaborators													$ 25,000,000
Non-cash royalty revenue recognized												$ 5,422,000
Revenue recognized										$ 15,894,625	$ 4,207,573		17,530,666	$ 31,163,416
Contract with customer, liability, revenue recognized													802,000
Asset impairment charges													0
Deferred revenue										2,575,000		2,575,000	2,575,000		$ 3,377,000
Capitalized contract , cost										0		0	$ 0
Stock Purchase Agreement [Member]
Deferred Revenue Arrangement [Line Items]
Proceeds from issuance of common stock						$ 35,000,000
Shares sold at the market, shares | shares						7,760
Collaborative Arrangement [Member]
Deferred Revenue Arrangement [Line Items]
Percentage of profit and costs sharing ratio						50.00%
Development Regulatory and Commercialization Milestones [Member]
Deferred Revenue Arrangement [Line Items]
Reserved right to elect to co-fund of development costs (as a percent)						30.00%
Development Regulatory and Commercialization Milestones [Member] | Minimum [Member]
Deferred Revenue Arrangement [Line Items]
Royalty payments on net sales (as a percent)						6.00%
Development Regulatory and Commercialization Milestones [Member] | Maximum [Member]
Deferred Revenue Arrangement [Line Items]
Royalty payments on net sales (as a percent)						12.00%
Incyte Corporation [Member]
Deferred Revenue Arrangement [Line Items]
Number of collaboration agreement programs | Program					4
Discovery period of antibodies development and commercialization period					5 years
Extended discovery period of antibodies development and commercialization period					3 years
Collaboration agreement termination notice period													12 months
Transaction price recognized										300,000			$ 800,000
Receivables for R & D services										10,900,000		10,900,000	10,900,000
Amount for R&D services provided										1,900,000		1,900,000	1,900,000
Achievement of milestone										9,000,000		9,000,000	9,000,000
Incyte Corporation [Member] | Stock Purchase Agreement [Member]
Deferred Revenue Arrangement [Line Items]
Shares sold at the market, shares | shares		10,000
Number of shares purchased, price per share | $ / shares		$ 6
Incyte Corporation [Member] | Collaborative Arrangement [Member]
Deferred Revenue Arrangement [Line Items]
Proceeds from Collaborators						$ 25,000,000
Royalty payments on net sales (as a percent)			15.00%
Upfront payment received related to clinical development					$ 20,000,000
Contract with customer, liability, revenue recognized										5,000,000			5,000,000
Additional license fees			$ 0
Project access fee			15,000,000										15,000,000
Total transaction price					25,000,000								73,700,000		68,400,000
Increase in transaction price													5,300,000
Actual and estimated variable consideration for development costs													48,700,000
Deferred revenue										2,600,000		$ 2,600,000	2,600,000
Incyte Corporation [Member] | Collaborative Arrangement [Member] | Topic 606 [Member]
Deferred Revenue Arrangement [Line Items]
Decrease to stockholders' deficit	$ 6,400,000
Decrease in deferred revenue	$ 6,400,000
Incyte Corporation [Member] | Collaborative Arrangement [Member] | Maximum [Member]
Deferred Revenue Arrangement [Line Items]
Potential milestone payments receivable			$ 510,000,000
Incyte Corporation [Member] | Agenus Inc [Member]
Deferred Revenue Arrangement [Line Items]
Number of collaboration agreement programs | Program				3
GSK Supply Agreement [Member]
Deferred Revenue Arrangement [Line Items]
Milestone payments for license costs									$ 5,000,000				5,000,000
Additional fixed fee for license costs								$ 7,300,000
Negotiation right expiry date							2017-03
Proceeds from negotiation right							$ 9,000,000
Proceeds from negotiation right creditable against future royalty payments							$ 2,500,000
Revenue fixed payments													19,300,000
Joint Steering Committee [Member] | Incyte Corporation [Member] | Collaborative Arrangement [Member]
Deferred Revenue Arrangement [Line Items]
Percentage of expected revenue			50.00%
Total development cost			$ 43,400,000
GSK Agreements [Member]
Deferred Revenue Arrangement [Line Items]
Total potential proceeds from license															$ 24,300,000
Royalty payments on net sales (as a percent)							2.00%
Period to receive license fees							10 years
Non-cash royalty revenue recognized										5,400,000			5,400,000
Decrease to stockholders' deficit													2,500,000
Decrease in deferred revenue													2,500,000
Merck Collaboration and License Agreement [Member]
Deferred Revenue Arrangement [Line Items]
Potential Payments													95,000,000
Upfront License Fee [Member] | Incyte Corporation [Member] | Collaborative Arrangement [Member]
Deferred Revenue Arrangement [Line Items]
Proceeds from Collaborators					$ 10,000,000								10,000,000
Upfront License Fee [Member] | GSK Supply Agreement [Member]
Deferred Revenue Arrangement [Line Items]
Proceeds from Collaborators									$ 3,000,000
License and Collaboration Revenue [Member]
Deferred Revenue Arrangement [Line Items]
Revenue recognized													22,400,000
License and Collaboration Revenue [Member] | Incyte Corporation [Member]
Deferred Revenue Arrangement [Line Items]
Revenue recognized													8,100,000
License and Collaboration Revenue [Member] | GSK Agreements [Member]
Deferred Revenue Arrangement [Line Items]
Revenue recognized											0			0
License and Collaboration Revenue [Member] | Merck Collaboration and License Agreement [Member]
Deferred Revenue Arrangement [Line Items]
Revenue recognized										4,000,000	0		4,000,000	0
Profit-share Products [Member]
Deferred Revenue Arrangement [Line Items]
Milestone payments for license costs						$ 20,000,000
Number of collaboration agreement programs | Program						2
Royalty-bearing Products [Member]
Deferred Revenue Arrangement [Line Items]
Milestone payments for license costs						$ 155,000,000
Number of collaboration agreement programs | Program						1
Research and Development Revenue [Member]
Deferred Revenue Arrangement [Line Items]
Revenue recognized										10,472,934	4,207,573		12,108,975	31,163,416
Research and Development Revenue [Member] | Balances without Adoption of ASC 606 [Member] | Topic 606 [Member]
Deferred Revenue Arrangement [Line Items]
Revenue recognized										8,631,000			10,848,000
Research and Development Revenue [Member] | Incyte Corporation [Member]
Deferred Revenue Arrangement [Line Items]
Revenue recognized										6,500,000
Research and Development Revenue [Member] | Incyte Corporation [Member] | Balances without Adoption of ASC 606 [Member]
Deferred Revenue Arrangement [Line Items]
Revenue recognized											$ 3,900,000			$ 30,800,000
Research and development services [Member]
Deferred Revenue Arrangement [Line Items]
Revenue recognized										1,144,000			2,307,000
Research and development services [Member] | Incyte Corporation [Member]
Deferred Revenue Arrangement [Line Items]
Revenue recognized										$ 1,100,000			$ 2,300,000

Revenue from Contract with Cu50

Revenue from Contract with Customers (Narrative) (Details 1) - Incyte Corporation [Member] - Research and Development Revenue [Member] $ in Millions	Jun. 30, 2018USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2018-07-01
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Expect to recognize deferred research and development revenue	$ 0.6
Revenue, remaining performance obligation, expected timing of satisfaction, period	6 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2019-01-01
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Expect to recognize deferred research and development revenue	$ 0.8
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2020-01-01
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Expect to recognize deferred research and development revenue	$ 1.2
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year

Revenue from Contracts with C51

Revenue from Contracts with Customers (Summary of Disaggregation of Revenue) (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Disaggregation Of Revenue [Line Items]
Revenue	$ 15,894,625	$ 4,207,573	$ 17,530,666	$ 31,163,416
Research and development services [Member]
Disaggregation Of Revenue [Line Items]
Revenue	1,144,000		2,307,000
License and collaboration milestones [Member]
Disaggregation Of Revenue [Line Items]
Revenue	9,000,000		9,000,000
Recognition of deferred revenue [Member]
Disaggregation Of Revenue [Line Items]
Revenue	329,000		802,000
Non-cash royalty revenue [Member]
Disaggregation Of Revenue [Line Items]
Revenue	5,421,691		5,421,691
United States [Member]
Disaggregation Of Revenue [Line Items]
Revenue	11,895,000		13,531,000
United States [Member] | Research and development services [Member]
Disaggregation Of Revenue [Line Items]
Revenue	1,144,000		2,307,000
United States [Member] | License and collaboration milestones [Member]
Disaggregation Of Revenue [Line Items]
Revenue	5,000,000		5,000,000
United States [Member] | Recognition of deferred revenue [Member]
Disaggregation Of Revenue [Line Items]
Revenue	329,000		802,000
United States [Member] | Non-cash royalty revenue [Member]
Disaggregation Of Revenue [Line Items]
Revenue	5,422,000		5,422,000
Europe [Member]
Disaggregation Of Revenue [Line Items]
Revenue	4,000,000		4,000,000
Europe [Member] | License and collaboration milestones [Member]
Disaggregation Of Revenue [Line Items]
Revenue	$ 4,000,000		$ 4,000,000

Revenue from Contracts with C52

Revenue from Contracts with Customers (Schedule of Information about Contract Assets and Contract Liabilities from Contracts with Customers) (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2018USD ($)
Contract With Customer Asset And Liability [Abstract]
Deferred revenue, Beginning Balance	$ 3,377
Deferred revenue, Deductions	(802)
Deferred revenue, Ending Balance	$ 2,575

Share-Based Compensation Plan53

Share-Based Compensation Plans (Narrative) (Details) - USD ($) $ / shares in Units, $ in Millions	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Weighted average grant-date fair value of options granted	$ 1.29	$ 1.94
Intrinsic value of shares vested	$ 0.2
Vesting of non-vested shares, shares	53,050
Shares issued from exercise of options	272,493
Employees and directors [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Unrecognized compensation cost, options	$ 10.7
Outside Advisors [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Unrecognized compensation cost, options	$ 0.8
Stock Options [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Unrecognized compensation cost, weighted average period	2 years 4 months 24 days
Restricted Stock [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Unrecognized compensation cost	$ 3.3
Performance Based Award [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Unrecognized compensation cost, weighted average period	2 years 8 months 12 days
2009 EIP [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Deferred Compensation Arrangement with Individual, Maximum Contractual Term	10 years
2009 EIP [Member] | Minimum [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Vesting period, minimum	3 years
2009 EIP [Member] | Maximum [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Vesting period, minimum	4 years
2009 ESPP [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Shares issued under ESPP	47,698

Share-Based Compensation Plan54

Share-Based Compensation Plans (Schedule Of Stock Option Activity) (Details)	6 Months Ended
	Jun. 30, 2018USD ($)$ / sharesshares
Share Based Compensation [Abstract]
Options Outstanding, Beginning Balance | shares	14,366,787
Options Granted | shares	3,795,918
Options Exercised | shares	(272,493)
Options Forfeited | shares	(610,260)
Options Expired | shares	(219,205)
Options Outstanding, Ending Balance | shares	17,060,747
Options Vested or expected to vest | shares	17,060,747
Options Exercisable | shares	9,751,852
Options Outstanding, Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 4.22
Options Granted, Weighted Average Exercise Price | $ / shares	5.46
Options Exercised, Weighted Average Exercise Price | $ / shares	3.41
Options Forfeited, Weighted Average Exercise Price | $ / shares	4.09
Options Expired, Weighted Average Exercise Price | $ / shares	5.26
Options Outstanding, Weighted Average Exercise Price, Ending Balance | $ / shares	4.50
Options Vested or expected to vest, Weighted Average Exercise Price | $ / shares	4.50
Options Exercisable, Weighted Average Exercise Price | $ / shares	$ 4.31
Options Outstanding, Weighted Average Remaining Contractual Term	7 years 4 months 17 days
Options Vested or expected to vest, Weighted Average Remaining Contractual Term	7 years 4 months 17 days
Options Exercisable, Weighted Average Remaining Contractual Term	6 years 1 month 6 days
Options Outstanding, Aggregate Intrinsic Value | $	$ 357
Options Vested or expected to vest, Aggregate Intrinsic Value | $	357
Options Exercisable, Aggregate Intrinsic Value | $	$ 357

Share-Based Compensation Plan55

Share-Based Compensation Plans (Summary Of Non-vested Stock Activity) (Details)	6 Months Ended
	Jun. 30, 2018$ / sharesshares
Share Based Compensation [Abstract]
Non-vested Shares Outstanding, Beginning Balance | shares	1,313,550
Non-vested Shares Granted | shares	791,829
Non-vested Shares Vested | shares	(53,050)
Non-vested Shares Forfeited | shares	(41,250)
Non-vested Shares Outstanding, Ending Balance | shares	2,011,079
Non-vested Shares Outstanding, Weighted Average Grant Date Fair Value, Beginning Balance | $ / shares	$ 2.91
Non-vested Shares Granted, Weighted Average Grant Date Fair Value | $ / shares	4.08
Non-vested Shares Vested, Weighted Average Grant Date Fair Value | $ / shares	3.77
Non-vested Shares Forfeited, Weighted Average Grant Date Fair Value | $ / shares	4.30
Non-vested Shares Outstanding, Weighted Average Grant Date Fair Value, Ending Balance | $ / shares	$ 3.32

Share-Based Compensation Plan56

Share-Based Compensation Plans (Schedule Of Share-Based Compensation Expense) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 1,585	$ 2,752	$ 3,790	$ 5,129
Research and Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	641	1,272	1,640	2,399
General and Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 944	$ 1,480	$ 2,150	$ 2,730

Benefit Plans (Narrative) (Deta

Benefit Plans (Narrative) (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, contributions by employer	$ 0		$ 0
Defined benefit plans, estimated future employer contributions for the remainder of fiscal year	$ 0		$ 0
Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, contributions by employer		$ 41,000		$ 83,000

Recent Accounting Pronounceme58

Recent Accounting Pronouncements (Narrative) (Details) $ in Millions	Dec. 31, 2017USD ($)
ASU 2016-02 [Member]
New Accounting Pronouncement Early Adoption [Line Items]
Operating leases expect to recognize assets and liabilities	$ 8.2

Subsequent Events (Narrative) (

Subsequent Events (Narrative) (Details) - Subsequent Event [Member] - Sales Agreement [Member] - B. Riley FBR, Inc [Member] shares in Millions, $ in Millions	1 Months Ended
	Aug. 09, 2018USD ($)shares
Subsequent Event [Line Items]
Aggregate net proceeds from issuance of common stock | $	$ 4.2
Shares sold at the market, shares	2.2
Shares remain available for sale	10.6